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The accrual of patients to cancer clinical trials has been noted by a number of authors as 
a significant problem. Research to date has examined a range of patient and physician 
related factors that may account for the low accrual rate. Patient refusal as a reason for 
non-participation has been found by previous research to account for a significant 
proportion of patients who are not entered onto a trial. This project aimed to explore the 
differences in attitudes and psychological variables between patients who refused a 
clinical trial and those who consented. 
A cross sectional, single point, postal questionnaire design was employed. Patients who 
were medically eligible for current phase I, II or III cancer chemotherapy clinical trials 
received a series of self-report questionnaires. These assessed personality, mood status, 
emotional expression and health locus of control, and patients' attitudes to research and 
hypothetical clinical trials. Follow up semi-structured interviews were held with a sub-
sample of participants. 
During the data collection period, 48 patients were identified as eligible for clinical 
trials. Of these, 95.9% consented to a trial. The results query previous fmdings that 
patient refusal is a significant problem in accrual to trials. Thirty-one patients (63%) 
returned the questionnaires and of these, none refused entry to a clinical trial. Statistical 
analyses showed that patients' attitudes to research were related to their Willingness to 
enter hypothetical clinical trials. An effect of personality and health locus of control on 
patients' perception of choice when offered a trial was found. Qualitative analysis 
revealed that the decision to enter a clinical trial was not difficult for patients, as had 
been previously proposed. Recruitment and methodological difficulties are discussed. 
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CHAPTER ONE : INTRODUCTION 
1.1 The Randomized Controlled Clinical Trial 
The systematic use of research evidence to improve health care has been promoted by 
the National Health Service (NHS) through it's Evidence-Based Medicine initiative 
(NHS Executive, 1996). The National Research and Development Directorate have 
established criteria by which the strength and quality of evidence may be judged 
(Bandolier 36, 1997). The highest level of evidence of treatment efficacy is obtained 
from systematic reviews of randomized controlled trials (RCTs). The single RCT 
provides the next level of evidence in the hierarchy. Hence, in the field of oncology the 
effectiveness of new treatments is frequently determined by randomized controlled 
clinical trials. These trials aim to quantify the degree of therapeutic effect and eliminate 
distorting biases (Tobias & Souhami, 1993). 
The recruitment of patients to RCTs is a long-standing difficulty. It has been estimated 
that less than 3% of cancer patients actually receive treatment as part of a clinical trial 
(Benson et al., 1991), although more recent studies suggest this has increased to 12% 
(Twelves et at, 1998; Spiro et at, 2000). The proportion of patients entered onto RCTs 
is thus far from satisfactory. Such low rates of recruitment compromise the rigorous 
scientific testing of a new treatment, which in turn leads to slow development and 
delayed availability (Cook-Gotay, 1991). In addition, low recruitment rates can result 
in small, selective patient subgroups, which may limit the application of results to the 
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rest of the population with the disease (Jack et aI., 1990; Quoix et aI., 1986). It is clear 
that maximizing recruitment to cancer clinical trials is of critical importance. 
The literature examining the question of why patients do not enter cancer clinical trials 
has been approached from a wide range of angles and from a variety of disciplines. 
Research to date has demonstrated that characteristics of the trials themselves, the 
physicians and of the patients all influence trial participation (Cook-Gotay, 1991). This 
review aims to critically examine the literature on patient-related factors that influence 
recruitment to cancer clinical trials. It will place particular emphasis on research that 
explores the relevance of psychological factors. 
Firstly, a more detailed explanation of the nature and purpose of clinical trials is 
required. 
1.2 Cancer Clinical Trials - Phase I, II & III 
In oncology, the evaluation of a new drug involves the progression from phase I trials 
through to phase III. Determination of the safety and effectiveness of the new 
treatments is the aim of the trials (Schwartsmann et aI., 1991). Phase I studies first try 
the new agent in patients with the aim of determining maximum tolerated dose and the 
toxicity profile in humans (Neal & Hoskin, 1997). Phase I trials are offered to patients 
for whom there is no other recognized treatment and less than 4% will achieve an 
objective response, whilst there is a high chance of unwanted side-effects (Estey et at, 
1986). Phase II studies seek anti-tumor activity based on doses and schedules from the 
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phase I study. Again, treatment is offered to patients for whom conventional therapy 
has failed or there is no effective recognized treatment (Neal & Hoskin, 1997). Phase I 
and II trials place physical and psychological demands on the patient, which lead to 
greater pressure, stress and uncertainty compared with conventional treatment (Hope-
Stone et al., 1997). Phase III trials compare the new agent with the best existing 
standard treatment. If there is no standard treatment a placebo is used. These trials 
require a large number of participants. 
Therefore, a clinical trial is not a unitary concept, although a shortcoming of research in 
this area is the failure to distinguish between different types of trial. 
1.3 Trials - Who Enters? 
Differences have been demonstrated between patients who participate in clinical trials 
and those who do not. In a review of the literature, Cook-Gotay (1991) states that 
patients entered onto protocol were in better condition, younger, heavier, of higher 
socioeconomic status and had better performance status. The author could not find 
evidence for differences in sex, race, marital status, religion or medical insurance 
coverage. 
Elderly patients are under represented in cancer clinical trials (Walker et al., 1998). 
There is also substantial evidence that elderly patients are not given biological optimal 
treatment for their disease, which may be due to oncologists not giving aggressive 
treatment on compassionate grounds (Walker et al., 1998). However, a study of 80 
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women with breast cancer showed older and younger women's views to be very similar. 
Receiving the most effective treatment was equally important for both groups, 
regardless of time in hospita~ side-effects and distance to travel (Walker et aI., 1998). 
It is important to note that many patients are not medically eligible for clinical trials. 
Medical ineligibility of a majority of cancer patients may account for the low 
participation rate. A review of the literature on accrual to cancer clinical trials showed 
that between 12 and 44% of patients are eligible for entry (Cook-Gotay, 1991). This 
has been supported by more recent work (e.g. Spiro et aI., 2000). Hence, medical 
ineligibility cannot account solely for the low proportion of patients entering RCTs. It 
has been shown that patient refusal is also an important factor. Spiro et al. (2000) state 
that 73.5% of their eligible lung cancer patients refused trial entry. Quoix et al. (1986) 
found that 20% of eligible lung cancer patients were not entered for non-medical 
reasons. Other researchers have demonstrated similar figures. Cook-Gotay (1991) 
highlights patient refusal as a reason for non-participation as ranging from 15 to 32%. 
Summary 
Accrual of patients to clinical trials is a problematic issue. There may be differences 
between those who enter and those who do not, and some groups are under represented. 
Although not all patients are medically eligible for trials, patient refusal is a significant 
factor in the low participation rate. 
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The research relevant to the question of ''why do patients refuse? " is reviewed in the 
following sections. To begin, individuals' general concepts of clinical trials and 
medical research will be examined. 
1.4 Attitudes Towards Clinical Trials 
Research to date has noted that patients make their decisions within a social setting, and 
so it is important to consider non-patients' attitudes towards trials as well as those of 
patients. Lay adults have reported favourable attitudes to the concept of clinical trials. 
In addition, individuals indicate their willingness to participate. Four hypothetical trials 
were presented to 1022 non-patients and two thirds said they would be willing to take 
part (Kemp et al., 1984). 
It has been argued that these positive attitudes towards clinical trial research do not 
differ between the general public and patients (Casseileth et aI., 1982). In a self-
administered questionnaire survey of the general public (n=107), cardiology patients 
(n=84) and cancer patients (n=104), it was found that most (71 %) believed that patients 
should serve as research subjects. The responses did not differ by demographic 
variables or subgroup. Increased scientific knowledge and potential benefits to others 
were cited as reasons in support of this belief. Seventy percent of the respondents 
thought the doctor had prior knowledge of the efficacy of the drug, which suggests that 
many did not understand the trial's underlying principle. 
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Other research has found that many people do not have an accurate understanding of 
clinical trials. Focus groups with women in the community and breast cancer patients 
revealed that most did not understand the need for trials, the manner in which they were 
conducted, the use of placebos or randomization. While trials were seen as a benefit to 
future generations, they were not thought to benefit the individual, for whom they were 
considered a gamble and a last resort (Ellis & Butow, 1998). 
It appears that there is an important difference between thinking about oneself and 
anonymous others (Casseileth et aI., 1982). It was demonstrated that participants were 
more self-concerned and less altruistic when asked about their own treatment. Evidence 
for this was also provided by a survey of patients who had already given informed 
consent for a chemotherapy clinical trial. 'Helping doctors through research' was one 
of the least important reasons for these patients (Penman et aI., 1984). 
Research indicates that while both patients and the general popUlation believe they 
should and would participate, it remains the case that many do not. The use of 
hypothetical trial descriptions in research may at least in part explain this discrepancy. 
It is questionable whether patient decision-making about actual trials is the same as 
hypothetical decision making. The latter situation has no implications for the 
individual's future, while the former has many. There is no literature comparing the 
two. 
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Patients' general attitudes towards medical care and research have been shown to 
influence how they perceive the manner and content of information disclosure for the 
trial into which they were enrolled (Verheggen et al., 1996). It may follow that prior 
attitudes influence a patient's decision to participate. In a review of the literature on 
decision-making issues for patients in clinical trials, Bujorian (1988) argues: 
"Patients often have a bias either towards or against clinical trials ..... Patients may 
make hasty decisions based on their biases. IJ 
For some, the trial offers a source of hope, but others fear experimentation. This view is 
in accordance with many anecdotal accounts of patient decision-making. However, 
Bujorian does not make it clear which research papers her conclusions are drawn from. 
Further research is required that examines a patient's attitudes and beliefs about clinical 
trials and how these impact on their decision about participating. 
Summary 
Patients and non-patients express positive views of clinical trials, although many may 
not have an accurate understanding of them. Hypothetical trial decision-making is 
likely to be different from a patient's decision-making about a real trial. Authors 
express the idea of a prior bias that influences a patient's decision, but this has little 
empirical support. 
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This review will now consider the research that directly focuses on reasons for 
participation and refusal. 
1.5 Specific Motivations and Barriers to Participation 
Authors have drawn attention to the fact that the proportion of patients excluded from 
protocols and the reasons for this are rarely documented (Antman et al., 1985; Lennox 
et aI., 1979). More recently, a number of studies have addressed this issue by directly 
asking patients about their reasons for refusing or agreeing to participate. 
A survey was conducted of 4281 individuals aged over 60 years who were enrolled into 
a hypotension trial. The fmdings revealed that contribution to science (96%), improving 
the health of others (96%) and improving one's own health (93%) were the most 
important reasons for joining the trial (Schron et aI., 1997). In a survey of individuals 
eligible for clinical drug trials conducted by a contract research organization (eRO), 
fmancial compensation, improvement of health and contribution to science were the 
main motivations for participation (Cunny & Miller, 1994). 
Research focusing on cancer clinical trials has revealed similar motivating factors. 
'Others will benefit' and 'trust in the doctor' were cited as the main reasons for 
participation by 147 patients who accepted entry to a cancer ReT (Jenkins & 
Fallowfield, 2000). In an earlier study, interviews were conducted with 144 patients 
currently enrolled in phase II or III cancer clinical trials. The primary motivations for 
participation were benefits outweighing risk, trust in the hospital, trust in the physician, 
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beliefs it would fight illness, belief that the illness would get worse without it and the 
information provided by the physician (penman et aI., 1984). 
These studies highlight the importance of altruistic motives and trust in the doctor for 
patients that agree to participate. Llewellyn-Thomas et al. (1991) argue that patients 
who participate in trials are more susceptible to the doctor's enthusiasm. However, it 
may be argued that the concept of social conformity is the underlying factor here, where 
patients that participate in a trial wish to give a ''yes'' response that will please the 
doctor. 
Social desirability may also playa role when patients are asked to state their reasons for 
participating. A 'desire to help others' may be perceived as a socially desirable 
response rather than more 'selfish' reasons such as 'improving my own health'. 
It has been noted that during illness people need to feel their needs are of top priority 
and the random assignment to a treatment program is not consistent with this (Schain, 
1994). Schain highlights the importance of whether a person is primarily altruistic or 
self-protective. An altruistic individual who gains gratification from contributing to 
scientific knowledge is more likely to participate. However, an individual who has a 
strong sense of autonomy and believes the function of medical care is to make the 
patient well again is unlikely to participate. While these observations are interesting, 
the author provides no evidence to support her views. 
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Barriers to patient participation have been named as: scheduling and family conflicts, 
and the amount of time required (Devris et aI., 1989). This research was not specific to 
cancer clinical trials. Another study focused on 68 individuals who were eligible for 
clinical drug trials, who considered participating, but did not. They cited schedule 
conflicts, risks involved and potential discomfort of the procedure as reasons for their 
refusal (Cunny & Miller, 1994). However it is unclear whether these individuals were 
healthy or suffering from disease. The authors did not state the type of drugs being tried 
or whether the trials were phase I, II, or III. The survey did use individuals involved 
with real protocols, but it is not clear how these results can be generalized to a 
population with cancer who must consider lifesaving treatment options. In addition, the 
survey was distributed by a Contract Research Organisation (Pharmaco-LSR) employee, 
which may have introduced bias into the results. 
Barofsky and Sugarbaker (1979) used standardized interviews to compare patients who 
had completed one of three sarcoma clinical trials (n=48) with those who had declined 
or dropped out (n=32). It was found that both groups gave reasons that were related to 
self-interest, but for those who refused participation, the aversive aspects of the 
treatments were more important. The authors found no differences in socio-
demographic variables or in psychosocial problems between the groups. They conclude 
that treatment-related factors were the major determinants of willingness to participate 
in the trials and state that: 
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"Patients were not, for the most part, non-participators for trivial or for psychological 
reasons'" 
However, this conclusion lacks supporting evidence as no standardized psychological 
scales or instruments were used. 
This study highlights some of the methodological weaknesses in this area of research. 
Here the 'non-participation group' included: patients who were not willing to be 
randomized into a protocol, patients with recurrent disease who refused further therapy, 
patients who withdrew from further therapy and patients who withdrew from the 
protocol after beginning treatment (for example, because they found their reaction 
unacceptable). This would appear to be a heterogeneous group. The authors saw no 
reason to separate these patient populations, but did not provide statistical evidence to 
support this judgement, probably due to an already small sample size. It may be the 
case that very different reasons and decision-making processes were present in these 
different subgroups. 
The authors recognized that the best time to interview patients was after they had 
completed treatment, or refused to enter or withdrawn from the trial. However this was 
not possible for approximately half the patients. These patients were interviewed by 
phone up to a few months later. This brings the validity and reliability of their 
responses into question. After this time lapse patients may not have been able to 
accurately recall their thoughts and reasons for the decisions they made. Research in 
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this area varies widely in terms of when in the trial process it is conducted. Evidence 
from qualitative studies suggests that a trial is a dynamic process where perceptions and 
views change as the trial progresses (Cox, 1999). It is thus difficult to make direct 
comparisons between studies that are conducted at different time points. 
Finally, a piece of research in this area that has included a psychological measure is that 
of Lovegrove et aI. (2000). They approached 150 women who were regular attendees at 
a clinic for those at high risk of breast cancer. The women had been offered 
participation in a 5-year Tamoxifen trial. This drug was being tried as a prophylactic 
agent against primary breast cancer in women at high familial risk of the disease. The 
trial was double-blind and placebo controlled. One hundred and six women agreed to 
enter the study, of which approximately 50% had agreed to the Tamoxifen trial and 50 
% had declined. 
The women who were in the trial were significantly older than those who were not. 
Socio-economic status was not related to participation. More women in the trial (40%) 
gave an altruistic reason (for example, wanting to help future generations) than those 
not on the trial (7.5%). The participants completed the Multi Dimensional Health Locus 
of Control scale (MDHLC). Scores on this measure were not related to participation, 
despite predictions that higher scores on internal locus of control would be found in 
those electing not to join the trial. Those who declined the trial were more aware of 
lifestyle factors that influence the development of cancers and found the information 
given about the trial drug more difficult to understand. 
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Lovegrove et al. (2000) used patients who were currently asymptomatic and were 
offered participation in a trial of a preventative agent. This population may differ 
greatly from those diagnosed with cancer and work of this nature is still required on 
treatment trials. Also, it should be noted that the questionnaires were filled in 
retrospectively to entering or not entering the trial and may have been influenced by 
experiences since the women made their decision. 
Summary 
Patients identify a range of reasons for their decision. Some of these are logistical and 
others are related to their beliefs. The area is plagued with methodological difficulties. 
Sample sizes are small and heterogeneous. Patients are interviewed at different time 
points in the trial, making it difficult to directly compare findings. The phase of the trial 
used may not be stated or different phases are used and treated as one. Research has 
focused on symptomatic patients, asymptomatic patients, prevention trials and 
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treatment trials. Making comparisons and draWing conclusions from the findings is 
thus problematic. 
The following section will examine the literature on the decision-making process in 
patients and its impact on clinical trial participation. 
1.6 Decision-Making and Desire for Information 
The need for health care professionals to provide information to patients so that they 
may participate in informed decision-making about their care has been recognized over 
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the past 10 years (Sutherland et at., 1989). Patients' desire for information and 
participation in decision-making has been investigated by several studies. Generally, 
conflicting results have been found. 
Many studies have shown that patients receive little information about their disease, 
tests and medication and that they would prefer to receive more (e.g. Faden et al., 1981). 
A strong association has been demonstrated between preference for information and 
participation in decision-making, especially in younger patients (Cassileth et al., 1980). 
Patients who are more highly educated have been found to want to participate in 
decision-making (Hack et al., 1994; Degner et al., 1997). However, sociodemographic 
factors have been shown to have no effect on preference by other studies (Ramfelt et al., 
2000). 
In one study, questionnaires about aspects of decision-making were administered to 210 
patients with hypertension (Strull et at., 1984). Patients were found to prefer more 
information about hypertension (41 %), whereas clinicians underestimated patient desire 
for discussion about their therapy. However, patients reported playing a passive role in 
actual decision-making, with 63% leaving the decision entirely up to the physician. 
Hence, while patients require information and discussion with clinicians, they may 
actually play a'limited role in decision-making regarding their treatment. The 
generalization of this study to cancer is of course questionable, although research on 
cancer populations has produced similar results. For example, Ramfelt et al. (2000) 
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studied 86 patients with newly diagnosed colorectal cancer and found that 62% 
preferred a collaborative role and 28% a passive role in treatment decision-making. 
When it came to their actual treatment decision, just 44% of the patients obtained their 
preferred role. 
Sutherland et al. (1989) administered the Health Opinion Survey, the Information 
Seeking Questionnaire and the Preference for Decision-Making Questionnaire to 52 
outpatients requiring post-surgery treatment for cancer. A positive association between 
information seeking and preference for participation in decision-making was found. 
Once again, patients concurrently felt that the physician should take primary 
responsibility in decision-making .. 
It is thus suggested by a number of studies that there is only a weak link between 
preferred and actual participating roles. It appears that patients' preferences for 
decision-making are related to factors other than their desire to be behaviourally 
involved. Sutherland et al. (1989) suggest that patients actively seek information to 
satisfy an aspect of 'psychological autonomy' and that this does not necessarily involve 
decision-making. They note Katz's (1984) defmition of psychological autonomy as: 
"The capacity of a person to become informed so that he/she may exercise the right to 
self-determination. " 
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Patients express their autonomy by 'deciding not to decide' and passing responsibility 
to the physician. 
Interestingly, research has shown that patients who play an active-role in decision-
making have better outcomes. Women with early-stage breast cancer had less anxiety 
and depression if given a choice of treatment than those who had no choice (Fallowfield 
et al., 1990). 
Qualitative investigations have produced fmdings consistent with the questionnaire-
based research (Cox & Avis, 1996). Cancer patients believed that the doctor was the 
best person to decide on the most appropriate treatment for them. They wanted to give 
control to the doctors and for them to take responsibility for decision-making. This 
appeared to be based on respondents' feelings they did not possess the background 
knowledge to make such a decision. 
There is an absence of research that investigates the relationship between decision-
making preferences and clinical trial participation. A recent study (Llewellyn-Thomas 
et aI., 1991) looked at whether patients who differed on clinical trial entry decision also 
differed in their attitudes towards decision control and the benefits associated with the 
trial arms. Sixty patients with a diagnosis of colon or rectal cancer participated. 
Twenty-five reported they would participate if faced with the choice, and 35 refused. 
Between group differences were noted, namely that those who would refuse 
participation reported lower scores for survival preference (that is, they were less 
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willing to tolerate short term toxicity for possible long term improved survival). This is 
consistent with other research that has found that aversive aspects of the trial itself were 
cited as reasons for refusal to enter (Barofsky & Sugarbaker, 1979). 
Those participants who were less willing to give away decision-making to the physician 
were more likely to refuse trial participation. The authors concluded that it is possible 
that patients who agree to clinical trials are more susceptible to the physician's 
enthusiasm for the trial. This has important ethical implications for the process of 
obtaining informed consent and raises questions about the personality and coping styles 
of those enrolled in trials. Coping has been divided into active, distractive and avoidant 
(Weisman & Worden, 1976) and has implications for behaviour such as information 
seeking, and so in turn may affect a patient's decision. 
Llewellyn-Thomas et al. (1991) demonstrated a link between a high desire for 
involvement in treatment decision-making and the lower likelihood of participation in 
clinical trial. It is noteworthy that 77% of the refusers cited 'aversion to randomization' 
as their primary reason. Randomization means that patients cannot predict or control 
the exact treatment they will receive. This may be intolerable to patients with a high 
need for control and decision-making. Research is needed that looks at the health locus 
of control and health beliefs of patients who are offered entry to a clinical trial. 
The study by Llewellyn-Thomas et al. (1991) has the merit of using cancer patients. 
However, the patients were not eligible for a clinical trial and so the researchers used a 
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hypothetical trial situation. Once again thinking about a hypothetical trial may yield 
different results from considering a 'real' trial. 
Summary 
Patients express a wish to have more information about their disease and to play an 
active part in decisions about their treatment. However, they concurrently feel that the 
'doctor knows best' and should make the final decision, perhaps as they do not possess 
enough background knowledge themselves. Patients with a high desire to participate in 
decision-making may be less likely to enter a clinical trial. It appears that decision 
making in medical care and especially that involVing clinical trials is relatively poorly 
understood. 
Central to the decision-making process is the issue of informed consent. Research 
investigating the impact of the informed consent process will be briefly reviewed. 
1.7 Informed Consent 
The informed consent process within the therapeutic research setting dates back to only 
the past 50 years (Daugherty, 1999). The concept generally refers to a patient's right to 
make an iiuormed choice regarding their health care. This must involve disclosure of 
the type of research, full disclosure of information about the trial, the risks and benefits, 
the unproven nature of the research, the alternatives to participation and the subject's 
right to withdraw without detrimental effects to their care. It is also implicit that the 
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patient should understand this disclosure. The content and comprehension of 
information may be an important influence on a patient's decision-making. 
The general conclusion from the literature is that the aims of informed consent are not 
met. In recent years concerns have arisen about the quality of written consent 
documents. In an analysis of the readability of five different surgical consent forms, it 
was found that all five were equivalent to undergraduate or graduate student material 
(Grundner, 1980). A larger study of nearly 100 consent forms, nearly 50% of which 
pertained to cancer clinical trials, found that consent forms were becoming increasingly 
lengthy and unreadable and did not improve patients' understanding (LoVerde et aI., 
1989). This appears not to have changed in more recent years, with the readability of 
consent forms for cancer research protocols still found to be at a level equivalent to at 
least 2 years of college education (Grossman et aI., 1994). The authors concluded that 
consent forms provide no meaningful written information to patients considering 
research participation. 
Research examining patients' use of consent forms supports this view. In a survey of 
100 breast cancer patients after they had signed written consent documents, it was found 
that the documents had little impact on patients' decisions or knowledge (Muss et aI., 
1979). Within one day of signing consent forms, 200 cancer patients showed major 
deficits in their recall of the purpose, nature, implications and risks of the therapy. 
Forty percent could not recall the purpose or nature of the procedure (Casseilth et aI., 
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1980). Similarly, a more recent study (Cox & Avis, 1996) found that patients had poor 
recall of the information given when being asked to participate in the trial. 
Hence, the research shows that patients have poor recall for the content of consent 
forms. It is possible that at the point of presentation, patients have limited ability to 
understand and process the information and that this later leads to difficulties with 
recall. If this is so, this suggests that patients make their decisions on little and poorly 
understood information and that fully informed consent is not obtained. This may 
support the view that patients have pre-existing views about clinical trials which are the 
major determinant of their decision. 
Patient interpretation of the consent form has been shown to affect participation in a 
hypothetical trial (Sutherland et al., 1990). Fifty cancer patients were asked to identify 
the information on a consent form that would be important if they were deciding 
whether or not to participate. Patients who refused to participate focused on the risks of 
the trial only (70%). In comparison, only 33% of patients who indicated that they 
would participate focused entirely on risks. Patients also made incorrect interpretations 
of some of the statements made on the consent forms. The authors concluded that many 
decisions regarding entry to clinical trials are made on the basis of incomplete or 
inaccurate information as patients misunderstand what is presented to them. 
The amount and type of information that should be given to patients with cancer when 
seeking their consent is greatly debated (Shaffer, 1982; Brewin, 1982). A balance is 
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required between respect for the patient's autonomy and active participation in 
decisions about their medical health care, and the potential anxiety and increased 
confusion that may result from too much disclosure (Grundner, 1980). There are a 
limited number of studies looking at the implications of different methods of consent for 
cancer clinical trials. One study used a randomized method to compare total disclosure 
of all relevant information with an individual approach at the discretion of the doctor 
(Simes et aI., 1986). Fifty-seven patients who were candidates for cancer clinical trials 
agreed to participate. Total disclosure led to a better understanding of the treatment, 
research and side effects. It also led to increased anxiety and less willingness to enter 
randomized treatment. 
Summary 
Patients may not understand the details of the trial being offered to them. They have 
been shown to have poor recall of the information provided during the informed consent 
process. Those patients who focus on the risks of the trial may be less likely to enter. 
Overall, many questions remain unanswered about the impact of informed consent on 
patients' decisions about clinical trials. It appears that patients have different needs 
regarding the amount and type of information they receive. Taking a more 
individualized approach may improve accrual rates. 
Personality is an intensively researched area in oncology. A brief overview of this 
complex and controversial area will be the aim of the following section. 
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1.8 Personality 
Some writers have suggested a cancer-prone personality that is characterized by 
abnormal suppression of negative emotions and the inability to express anger (e.g. 
Watson et aI., 1984; Copper and Faragher, 1993). However, research also indicates that 
emotional repression is a reactive rather than causal phenomenon in cancer patients 
(Kreitler et al., 1993). 
Cancer patients have been shown to have high ratings on the 'Lie' or 'social 
conformity' scale of the Eysenck Personality Questionnaire (Greer & Watson, 1975). 
This scale had been implicated in survival (Ratcliffe et al. 1995). Patients who score 
highly on 'social conformity' may be more willing to please the doctor by entering the 
trial. Also using the Eysenck Personality Questionnaire, Lloyd et al. (1984) studied 40 
patients with malignant lymphoma. Those who scored highly on the 'Neuroticism 
Scale' expressed greater dissatisfaction with the information and communication 
provided about their treatment. The authors suggested that personality assessment 
should be part of studies looking at patient-doctor communication. 
It can be seen that personality style may affect the way in which patients perceive the 
trial and their options, and in turn affect their decision regarding trial entry. The 
personality characteristics of individuals who enter clinical trials are a neglected area of 
the literature. 
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Cami et al. (1989) compared a group of 62 healthy male university students who 
participated in phase I clinical trials with a control group with similar sociocultural 
characteristics. Higher 'Extraversion' and 'Psychoticism' scores on the Eysenck 
Personality Questionnaire were found in the trial participants. There were no 
differences in the L-Scale. Hence, the results indicated a greater degree of impulsivity 
and sociability in the trial participants. E and P correlate positively with sensation 
seeking (Furnam, 1994) and therefore the authors conclude that volunteers may have a 
greater tendency to risk-taking behaviour. Sensation-seeking may be an important 
personality characteristic involved in decision-making concerning clinical trials. 
In addition, lower 'Neurotisicm' scores were found in the volunteer group, which 
suggests a lower susceptibility to stress situations. Individuals who scored highly on the 
'Neurotisicm' scale would be predicted not to participate in phase I trials. The authors 
conclude that the personality characteristics of individuals who enter phase I trial may 
influence the psychodynamics of the drug under investigation. 
These conclusions are not necessarily applicable to cancer treatment clinical trials. 
This research focused on healthy male, university volunteers who were involved in 
phase I trials. The personality of patients who consent to, or refuse to enter, cancer 
clinical trials (phases I-III), has not yet been investigated. 
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Summary 
The literature on cancer and personality is an extensive area, but it remains a neglected 
area of the research focusing on clinical trial participation. It is not possible to draw 
conclusions from the research to date. 
1.9 Family Factors 
A further field of research that has been largely neglected by the clinical trials literature 
is the impact of the family on a patient's decision. The family is usually the most 
important source of psychological support for the cancer patient (Holland, 1996). 
Tabak (1995) describes how patients' decisions about their treatment are not made 
independently. In a study of cancer patients' activities that precede a decision to agree 
to or refuse experimental treatment, Tabak (1995) states that: 
"Cancer patients speak of consulting extensively with friends and family, in addition to 
the doctor, before making up their minds. " 
Patients often need reassurance from family and friends, although the fmal decision is 
theirs (Penman et al., 1984). However, this support has been found to be an excessive 
pressure to accept experimental treatment for some patients (perr~ 1981). Families may 
wish to leave "no stone unturned" (Holland, 1982). 
The influence of family members' views on experimental treatment and their impact on 
the patient's decision-making has not been systematically studied. 
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1.10 Health Models 
Several theories and conceptual models have been developed that aim to predict the 
health behaviour of individuals. These may be used to explain the behaviour of patients 
faced with a decision regarding a clinical trial. 
The Health Belief Model (HBM) initially developed by Rosenstock (1966) and later by 
Becker and Maiman (1975) was fIrst used to predict preventative health behaviours. It 
has more recently been applied to a wide range of health-related behaviours. The model 
predicts that behaviour is the result of a set of core beliefs that have been redefmed 
throughout the person's life. The probability that a person will perform a particular 
health-related behaviour is influenced primarily by four core beliefs: the perceived 
seriousness of the disease, the perceived chance of getting disease, the perceived 
benefIts of the behaviour and the costs and barriers of action. It also suggests a 
stimulus, a 'cue to action', is needed to trigger the decision-making process. 
Four common concepts of the HBM and three other theories of health-related behaviour 
and how these may be applied to clinical trial participation have been described 
(Morrowet aI., 1994): 
Probability is the perceived likelihood of having the medical condition and of an 
expected outcome. Probability factors that may be important in the enrollment of 
patients in clinical trials include the individual's perception ofthe disease and the ability 
ofthe intervention to cure it. 
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Severity refers to the individual's perception of the severity of the disease or side 
effects. Severity factors important in the enrollment of patients into clinical trials 
include the patient's willingness to make trade-offs between survival and quality of life. 
Effectiveness refers to the patient's perception of the probable success of the treatments 
in the trial. Their personal beliefs, altruistic motives, fears that the condition will 
worsen and desire to get the best care possible are all effectiveness factors that may 
affect participation. 
Finally, Perceived cost is the sum of perceived barrier factors. These may include the 
patient's attitudes to randomization and research in genera~ and their degree of 
preference to participate in medical decisions. Other logistic costs may be of influence 
here, such as travelling time, cost and inconvenience. 
Morrowet al. (1994) noted the confusion between accrual to randomized cancer control 
trials and randomized cancer treatment trials. The former deals with prevention, 
screening and detection and the latter with treatment, cure and side effects. The four 
concepts described above apply differently to each. Severity and probability have 
minimal influence to treatment clinical trials, where as cost and effectiveness playa 
much greater role. 
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Research that has directly applied the models of health behaviour to cancer treatment 
clinical trials is limited. However, an extended form of the HBM was used to explain 
participation behaviour in clinical trials by Verheggen et al. (1998). The authors present 
a model of explanation for trial participation. A measurement of the influence of 
important others and of the patient's locus of control were incorporated in the model. 
The survey comprised a sample of 198 patients who were approached and asked to 
participate in a clinical trial. They were derived from different departments: surgery, 
dermatology, ENT, internal medicine, urology, cardiology, radiology, anesthesiology, 
orthopaedics and pulmonology, giving a total of 26 clinical trials. Data were collected 
through personal interviews from those patients who agreed and those who declined 
participation. 
A distinction was made between 'Old cases' (those with health problems dating back 
more than 3 months) and 'new cases' (those with no prior health problems until 
developing symptoms in the 3 months before the trial). Motivation for trial 
participation differed between these two groups. The 'new cases' tended to participate 
if they expected to run low risks and get better treatment in the trial and if they worried 
about their health. The 'old cases' were more motivated by getting treatment as quickly 
as possible and by the hope for higher personal. comfort in the trial, rather than the 
expectation of better medical treatment. 
31 
The results of the locus of control analysis showed that patients who felt powerless on 
health matters as shown by a high score on the chance scale, had lower expectations of 
personal comfort in the trial and hence were less likely to participate. In contrast, 
patients with a high score on external locus of control, indicating a high reliance on the 
physicians to solve their medical problems, had a higher chance of trial participation. 
The authors conclude that patients make a decision about a clinical trial by making a 
personal balance account. They weigh up the beliefs for and against it. The physical 
and emotional value patients hope to gain from participation, compared with the 
standard treatment, minus the trial risks and cost, form this personal balance account. 
This was found to depend upon the amount a patient felt physically threatened by their 
illness, how they regarded their illness and their opinions on medical care. 
However, it is notable that the response rate to the survey in the non-participants was 
significantly lower than in the participants. This appears to be a significant problem in 
research in this area and questions the representativeness of samples of patients who 
decline entry to clinical trials. It was also not clear which 'locus of control' scale was 
used and no evidence of its reliability and validity are given. The HBM is criticized as 
being highly abstract. It uses concepts that are difficult to defme (Gillam, 1991) and 
measure, and assumes individuals are rational information processors (Ogden, 1996). 
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Summary 
A patient's decision-making regarding a clinical trial may be conceptualized in terms of 
the Health Belief Model, where the patient makes a personal balance account based on 
their beliefs about their illness and the gains and risks of the trial. Research in this 
area has shown that patients with a high external locus of control are more likely to 
enter a trial. However, health models have been criticized on theoretical grounds. 
1.11 Individual Experience of Clinical Trials 
Cox (1998) highlights the absence of work that addresses the experience of 
experimental treatment of cancer from the viewpoint of patients themselves. Most work 
to date is quantitative in nature and conducted at the beginning of the trial, which leads 
to neglect of how the individual adapts to, makes sense of and ultimately reflects on the 
whole trial experience. Patients involved in clinical trials may provide unique insights 
into the whole trial experience which may be used to improve the way trials are 
conducted, right from the informed consent process to ending the trial and aftercare. 
Cook-Gotay (1991) suggests that work should focus on the patients' motivations, 
understandings and perspectives of the trial. There are a limited number of studies that 
use a qualitative methodology. 
A pilot study (Cox & Avis, 1996) aimed to give greater attention to patients' 
experiences of clinical trial participation. The informed consent process, reasons behind 
decision-making concerning participation and the impact of participation on the 
patients' lives were explored. The study reports the views of 7 patients as they 
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progressed through an anti-cancer drug trial. Six patients were enrolled on phase II 
trials and one on a phase I trial. Semi-structured interviews were conducted on three 
occasions throughout the trial process. 
The participants gave hope, a desire to help others, feeling they had no other choice, 
family pressure and a wish to take part in the research as reasons for participating. The 
authors highlight concepts of hope and choice as needing further inquiry in terms of 
what they actually mean to patients. They note the inherent conflict in the process of 
accrual to clinical trials where a patient is being asked to make a choice in a situation 
where they feel they have little knowledge and control, and where they perceive they 
have no choice. 
The results need to be interpreted with caution due to the small sample size. However, 
other research has shown that patients perceive the trial as their only option (Cobb et aI., 
1954). More recent research has used larger samples and two studies that are of 
particular interest are described below. 
Using Grounded Theory, Stetz (1993) interviewed 24 patients with advanced liver 
disease over a 6 month period, before, during and after receiving experimental treatment 
for cancer. Sixteen spouses were also interviewed. Stetz described the primary 
psychosocial process of individuals involved in experimental treatment as 'survival 
work'. That is, behaviourally and cognitively choosing life over death, or choosing 
treatment as opposed to letting the disease take its course. Reasons for engaging in 
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'survival work' were feeling there was no other option, fear of dying, desire to survive, 
a need to do something, believing the treatment would work and being offered the 
opportunity to try something. At the time of decision-making, patients and spouses 
gathered information to help or support their choice. 
The actual treatment period was experienced as 'suspended time' both behaviourally 
and psychologically. During this time patients were alert to signs of their disease and 
the effects of treatment. Finally, after the trial had ended, 'carrying on' was the main 
process for patients and their spouses. They needed to carry on with life without the 
hope that the treatment was a cure and they desired to live as normally as possible. 
Cox (2000) used semi-structured interviews to obtain the views of 55 patients offered 
participation in a phase I or II clinical trial. Patients were interviewed at 4 points during 
the trial process. The research focused on their recruitment experiences, decision-
making, reasons for participation, experience of the trial and the meaning of the trial. 
Patients also completed 2 quality of life measures; the Hospital Anxiety and Depression 
Scale (HADS) and the European Organisation for Research and Treatment of Cancer 
(EORTC). At follow up, the sample size had reduced from 55 to 27 patients. 
There were no statistically significant fmdings from the questionnaire data. However, 
the interview data gave important insights. At the recruitment stage the trial offered 
hope for some patients, a chance to help themselves and to help others. Eighty percent 
wanted the professionals to present them with the information and advise them what to 
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do. Accepting seemed the right thing to do as it was what the doctor had offered. 
Reasons for accepting were similar to those found in earlier studies: wanting to help 
others, desire to be in expert hands, feeling they had no choice and they had nothing to 
lose. 
An increasing sense of being burdened (e.g. side-effects, trips to hospital) by the trial 
was identified as patients progressed through the trial. Similar to Stetz's notion of 
'suspended time', patients felt their life was on hold for the trial duration. However, the 
trial also gave patients a sense of purpose, which enabled them to continue. At trial 
conclusion, patients viewed participation as a positive thing despite being disappointed 
by the clinical outcome. Cox (2000) concluded that: 
" ... Trial participation ... is a dynamic process, that has different meaning and impact 
according to the stage of trial involvement the patient is experiencing. " 
These two studies show that clinical trials are a process that begins when the trial is 
offered to the patient and continues even after the trial has ended. The qualitative data 
provide support for many of the quantitative studies described earlier. The fmdings 
highlight the importance of concepts such as hope, desire to help others and the trial 
being the only option. These insights may be useful in improving communication with 
patients and their care. Steltz concludes that the findings imply that clinically, cancer 
nurses can assess and support the 'survival work' of patients and their relatives. By 
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being aware of the experience of a clinical trial, nurses can help the patient adjust to the 
uncertainties of the disease and treatment. 
It is noteworthy that 58% of patients in the study by Cox (2000) said that the offer of the 
trial generated uncertainty. This draws attention to the confusion many patients 
experience at this time. A personal account of being offered entry to a clinical trial 
remarks on the great stress and bewilderment inherent to the situation (Thornton, 1992): 
(II cannot understand how a woman can properly judge the proposal that has been put 
to her .... " 
The author comments on the feelings of isolation and overwhelming nature of the 
decision: 
(I ••• To ask your average woman-in-the-street to have to decide whether or not to take 
part at the moment she has just been told she has a carcinoma would seem to be asking 
just too much. " 
Although this is an account of just one patient's views, Thornton draws attention to the 
fact that being offered a trial can be an immensely stressful and unwanted experience. 
As in other research, she describes how she hoped to have her treatment decided by a 
confident physician, and was instead left to decide for herself. The majority of research 
to date has focused on patients who have agreed to participate and speaks of the hope it 
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-offers them. No qualitative studies have explored trial refusers' experience of being 
offered the trial or how they later feel about their decision. Studies that do include 
patients who have refused the trial are limited and only ask for surface reasons for 
refusal. We know very little about the motivations, concerns, coping, emotional status 
or views of these patients. 
Thornton also draws attention to the fact the patient must make decisions about their 
treatment at a time when they have just received possibly devastating news. Cancer is 
one of the most feared diseases of all (Cox, 1984). For many, the word cancer means 
death, disfigurement and physical dependence (Holland, 1996). Hence, patients are 
likely to have difficulties coping with the situation. It is important to understand the 
psychological reactions of patients in order to understand their decision-making at this 
time. This leads us to a brief consideration of the literature on the psychological impact 
of cancer diagnosis. 
1.12 Psychological Reactions to Cancer 
The period following diagnosis is characterized by great emotional distress. Anxiety 
and depression are the predominant symptoms and these may be within the morbid 
range on psychiatric interview (Lloyd et al., 1984). Emotional reactions to an abnormal 
mammogram have been found to be shock, followed by numbness and disbelief as 
medical investigations proceed. Patients have high anxiety at this point and then a 
diagnosis of breast cancer leads to rage, sadness and despair (Massie & Holland, 1989). 
The diagnosis of a recurrence results in the same emotional reactions of terror, shock 
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and disbelief as the woman is thrown "back to the beginning", yet this time with the 
added burden of "preparing for the inevitable" (payne et al., 1996). The patient has to 
decide if she can commit to treatment that will cause discomfort. 
Anxiety and depression have been found to peak after breast cancer diagnosis and 
gradually decline over the next year (Vinokur et al., 1990). It is difficult to establish 
what is 'normal' sadness and worry in these patients. Studies report a point prevalence 
of depression in cancer patients ranging from 1.5% to 50% (Colon et al., 1990; Fras et 
al., 1967). The general consensus is that one in four patients suffer from depression 
(McDaniel et al., 1995). Similarly, 20 to 25% of patients experience anxiety at a 
clinical level (e.g. Cella et aI., 1993). Decision-making problems are common 
(Ibbotson et aI., 1994). Consequently, the mood status of the individual may have 
important implications for the clinical trial proposal. 
There are individual differences in the way patients respond to diagnosis. 
Developmental life-cycle stage may determine the response. Older people have been 
found to be less distressed following the diagnosis of cancer than younger people. For 
example, Harrison and Maguire (1995) assessed 520 patients aged between 18 and 75, 
within 8 weeks of diagnosis of a range of cancer types. A point prevalence of anxiety 
and depression disorders was found to be 17.1 %. These cases were significantly 
younger. 
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Similarly, Cassileth et ai. (1986) also found highly significant age differences for scores 
of anxiety, depression and general positive affect in 1278 patients with cancer. Similar 
results have been found in groups of patients with breast cancer, colorectal cancer (Mor 
et aI., 1994), and gynaecological cancer (Paraskavaidis et aI., 1993). In the latter of 
these studies higher levels of anxiety or depression on the Hospital Anxiety and 
Depression Scale were associated with greater dissatisfaction with the information 
received. 
A woman's coping abilities may affect her response. Avoidant coping and denial have 
been associated with greater distress in women with breast cancer (McCaul, 1999). 
Greater emotional expressiveness has been associated with improved adjustment (e.g. 
Classen et aI., 1996). Social, cultural, fmancial, familial factors and degree of 
emotional support all influence adaptation to cancer (Rowland & Massie, 1996). 
Summary 
Depression and anxiety are commonly found in cancer patients and are more severe 
immediately after diagnosis. A patient's emotional reaction may depend on their 
coping abilities and a variety of other social and personal factors. A decision 
regarding a clinical trial is made during an emotionally stressful time. 
1.13 Psychological Factors and Prognosis 
A further field of research is that concerned with psychosocial predictors of cancer 
course and survival. A complete review of this area is beyond the scope ofthis review. 
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However, the relevant studies will be described. Psychosocial factors may influence 
patient participation in clinical trials, which may lead to unrepresentative trial groups. 
These groups mayor may not have a greater chance of survival. 
Patients with good quality of life scores are associated with a better response to 
chemotherapy (e.g. Coates et aI., 1992) and with prolonged survival in patients with 
advanced disease (e.g. Earlam, 1996). A 'fighting Spirit' and emotional expressiveness 
(Greer, 1991), denial (Schulman et al., 1993), and outgoing personality (Stavraky et al., 
1988) have all been associated with longer survival time (Butow et al., 1999). It is 
important to note that these relationships have not been shown to be causal. 
Ratcliffe et al. (1995) found that high depression scores on the HADS and high L-scores 
on the Eysenck Personality Inventory (EPI) at diagnosis were independent prognostic 
factors for death at 5 years in 63 patients with lymphoma who received chemotherapy. 
Walker et al. (1999) studied 96 women with advanced breast cancer. High HADS 
depression and anxiety scores were independent predictors of poor response to 
chemotherapy. 
In a recent study, Watson et aI. (1999) investigated the effect of psychological response 
on outcome at 5 years in 578 women with early stage breast cancer. A high score on the 
depression category of the Hospital Anxiety Depression Scale (HADS) was associated 
with an increased risk of death, as was a high level of hopelessness and helplessness. 
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Emotional control as measured by the Courtauld Emotional Control Scale (CEC) did 
not have an impact on survival. 
It can be seen that patients' mood, coping and personality may influence survival. If 
these variables influence patients' participation in clinical trials, they have important 
implications for the generalization of the trial fmdings. 
However, research in this area is inconsistent and contradictory in its fmdings. Many 
research fmdings have failed to support any link between psychosocial factors and 
response or survival. Tross & Herndon (1996) found no evidence of the contribution of 
psychological factors to survival in 280 women with stage II breast cancer. Other 
studies have also failed to fmd an association (e.g. Jamison et aI., 1987). 
Summary 
The link between survival and psychological factors has produced contradictory 
findings. Studies suffer from methodological problems such as short follow-up periods, 
small sample sizes, failure to control for prognostic medical variables, and use of 
unreliable psychometric scales. Yet despite these shortcomings, the associations 
demonstrated are important considerations for the clinical trial literature. 
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Summary of the Literature Review 
The research on patient-related factors that influence accrual to cancer clinical trials has 
produced varied results. Differences have been demonstrated between patients who 
enter and those who refuse clinical trials. We know more about the characteristics of 
those who agree to enter, than those who refuse. This remains a neglected area. 
This review has highlighted the importance of patients' beliefs about the trial, the trial's 
benefits and costs, decision-making preferences and patients' own health in general. It 
has speculated that factors such as personality, family views and coping may also be 
important. The decision-making process has been shown to be complex and subject to 
individual differences. 
Research has moved towards viewing the trial as a dynamic process that has different 
meaning for different individuals. A patient's decision regarding a trial needs to viewed 
in the context of their emotional status at that time. 
There are few research studies looking at the impact of psychological factors, and to a 
large extent the contribution of psychological theory has been excluded or dismissed. 
Psychological problems are common and sometimes severe in patients with cancer 
(Lloyd et al., 1984) and yet the impact of these on a patient's decision regarding a 
clinical trial has not been investigated. 
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Finally, there are many methodological problems throughout the literature. Samples 
may mix patients with different types of cancer, and those with newly diagnosed and 
recurrent disease. Research has examined phase I, II and III trials, all of which have 
different implications for the participants and so are not always directly comparable. 
Samples are often small and characterized by low response rates, especially in the 
patient groups who decline entry to the trial. There is also a deficiency of standardized 
psychometric scales used in the research and most studies fail to report any reliability 
and validity statistics of those that have been constructed. Finally, research has often 
used participants for whom the decision and problem are not highly salient. The use of 
hypothetical scenarios has been criticized on grounds of validity by other authors and it 
is important that future research addresses this problem. 
This research aims to overcome methodological weaknesses of previous research by 
focusing only on chemotherapy phase III trials. Surgical and preventative trials will be 
excluded and the research will focus on newly diagnosed patients. It aims to explore 
both the views of patients who consent and those who refuse to enter a clinical trial. The 
research will investigate the validity of using hypothetical trial scenarios as a measure 
and will address the lack of research considering psychological factors by using 
established psychometric scales. 
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AIMS AND HYPOTHESES 
This study aims to examine the impact of various psychological factors on cancer 
patients' decision to accept or decline a clinical trial. It also aims to examine the 
influence of relatives' attitudes on this decision. 
1. General Attitudes 
Research Hypothesis 
Prior attitudes towards clinical trials (as measured by a 13-item, 5-point Likert scale 
questionnaire) will affect a patient's decision to enter or refuse a clinical trial. 
Null Hypothesis 
Prior attitudes towards clinical trials (as measured by a 13-item, 5-point Likert scale 
questionnaire) will not affect a patient's decision to enter or refuse a clinical trial. 
2. Predictions of Own Behaviour 
Research Hypothesis 
'Willingness to participate' in a cancer clinical trial (as measured by 4 hypothetical 




'Willingness to participate' in a cancer clinical trial (as measured by 4 hypothetical 
scenarios, on 5-point Likert scales) will not affect a patient's decision to enter or refuse 
a clinical trial. 
3. Emotional Expression 
Research Hypothesis 
There will be a difference in the level of emotional expression (as measured by the 
Courtauld Emotional Control Scale) between patients who refuse clinical trial 
participation and those who consent to a trial. 
Null Hypothesis 
There will not be a difference in the level of emotional expression (as measured by the 
Courtauld Emotional Control Scale) between patients who refuse clinical trial 
participation and those who consent to a trial. 
Emotional expression is not hypothesized to affect decision making, rather it is a factor 
that has been implicated in survival. Differences that exist between trial participants 
and those who refuse to participate may bias the trial's results. Emotional expression 
may need to be controlled for in cancer clinical trial research 
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4. Personality Styles 
Research Hypothesis 
Personality style (as measured by the Eysenck Personality Questionnaire - short form) 
will affect a patient's decision to enter or refuse a clinical trial. 
Null Hypothesis 
Personality style (as measured by the Eysenck Personality Questionnaire - short form) 
will not affect a patient's decision to enter or refuse a clinical trial. 
5. Mood Status 
Research Hypothesis (A) 
Level of depressed mood (as measured by the Hospital Anxiety Depression Scale) will 
affect a patient's decision to enter or refuse a clinical trial. 
Null Hypothesis (A) 
Level of depressed mood (as measured by the Hospital Anxiety Depression Scale) will 
not affect a patient's decision to enter or refuse a clinical trial. 
Research Hypothesis (B) 
Level of anxiety symptoms (as measured by the Hospital Anxiety Depression Scale) 
will affect a patient's decision to enter or refuse a clinical trial. 
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Null Hypothesis (B) 
Level of anxiety symptoms (as measured by the Hospital Anxiety Depression Scale) 
will not affect a patient's decision to enter or refuse a clinical trial. 
6. Health Beliefs 
Research Hypothesis 
Health locus of control (as measured by the Multidimensional Health Locus of Control 
Scale) will affect a patient's decision to enter or refuse a clinical trial. 
Null Hypothesis 
Health locus of control (as measured by the Multidimensional Health Locus of Control 
Scale) will not affect a patient's decision to enter or refuse a clinical trial. 
7. Relatives' General Attitudes 
Research Hypothesis 
Relatives' prior attitudes towards clinical trials (as measured by a 13·item, 5-point 




Relatives' prior attitudes towards clinical trials (as measured by a 13-item, S-point 
Likert scale questionnaire) will not affect a patient's decision to enter or refuse a clinical 
trial. 
8. Predictions of behaviour 
Research Hypothesis 
Relatives' 'willingness to participate' in a cancer clinical trial (as measured by 4 
hypothetical scenarios, on S-point Likert scales) will affect a patient's decision to enter 
or refuse a clinical trial. 
Null Hypothesis 
Relatives' 'willingness to participate' in a cancer clinical trial (as measured by 4 
hypothetical scenarios, on 5-point Likert scales) will not affect a patient's decision to 
enter or refuse a clinical trial. 
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CHAPTER II-METHODOLOGY 
2.1 Original Design 
This original aim of this research was to explore the differences between patients who 
consented to a cancer clinical trial and those who refused. It focused on cancer patients 
who were eligible for a clinical trial and asked them to complete psychological and 
attitudes measures. The measures examined patients' opinions about clinical trials and 
their views concerning their own participation if faced with the decision. The patients' 
current mood status, emotional expression, health beliefs and personality characteristics 
were also assessed by the measures. After completing the measures the patients were 
asked to enter the cancer clinical trial for which they were eligible. Their decision was 
recorded and used in this research. Figure 1 illustrates the original design. 
Figure 1. Original design of the research 
Oncology patient pool 
eligible for current clinical trials 


















It is shown that patients who agreed to enter this study would form two groups, 
according to whether they consented to, or refused to enter the clinical trial proposed to 
them. This study aimed to focus on groups A and B and to compare the scores on the 
attitudes scales and psychological measures ofthese two groups. 
A cross sectional, single measures point, postal survey design, was implemented. Both 
standardised, established self-report measures and newly designed questionnaires for 
this study were used. The measures that were selected aimed to detect differences 
between the two groups of patients. Their selection was based on the fmdings of 
previous research and/or aimed to address areas neglected by previous studies as 
highlighted in the literature review. Consideration was taken of the reliability and 
validity data of the measures during selection. 
Questionnaires were sent immediately after the eligible referral was received by the 
Oncology Department, or in the case of in-patients, when a patient was considered 
eligible for a trial. This time point was chosen so that the patients received the 
questionnaires before being approached by their consultant about a cancer 
chemotherapy trial. This was considered necessary so that the trial information the 
patients received did not influence their responses to the questionnaires. 
In a qualitative follow-up phase, an in-depth, semi-structured interview was offered to 
those patients who had returned the questionnaires, after they had received 3 cycles of 
treatment. This aimed to explore patients' recollections about their decision-making 
regarding the trial, their attitudes towards trials and research, and any changes that may 
have occurred since beginning their treatment. This time-point was chosen fIrstly as it 
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was felt that patients would have some experience of trial or non-trial treatments, but 
would still be close enough to have reliable recollections of when they made the 
decision. Secondly, the time constraints of the study meant that a longer period was not 
possible. 
2.2 Modifications to Design 
The original design and alIns of the research had to be modified due to the 
characteristics of the responders. It became apparent that the number of patients 
agreeing to this research and refusing clinical trials was going to be very low. In fact, 
the fmal sample contained no patients in group B (see figure 1). Therefore, a single 
group design was required. 
The revised design, showing the data obtained from each group is shown in figure 2. 
The research aims were modified to explore the characteristics and responses on the 
measures of the patients within group A. The focus of the research became the 
characteristics of patients who consented to a cancer clinical trial and were willing to 
participate in this research project. This group was also compared with groups B and C 
on basic demographic information (See figure 2). 
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Figure 2. Modified research design 
Oncology patient pool 
eligible for current clinical trials 
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Successive patients who fulfilled inclusion criteria (see Appendix I) to participate in 
current phase I, II or III cancer chemotherapy randomized clinical trials at an Oncology 
Department in the North East of England were asked to participate in this study. The 
initial plan was to only include patients eligible for phase III trials, however in order to 
increase the sample size patients eligible for phase I and II trials were included. 
Surgical trials were excluded in order to obtain an as homogeneous group of patients as 
possible. The time period from November 2000 to April 2001 was selected. 
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Participants were allover 18 years of age and were male or female. Each patient was 




Participants filled in a short questionnaire asking for personal information. Their age in 
years and marital status were recorded. The number of years of education a person had 
completed and their occupation were also recorded. Participants were asked to state any 
other medical problems and stressful life events that had occurred in the last 6 months. 
Disease Related Information 
The medical records of the patients who participated in this study were consulted at the 
end of the data collection period. The number of months since the diagnosis of the 
cancer for which the patient was approached about a trial was recorded. The number of 
previous treatments and of diagnoses of cancer the patient had received were recorded. 
In addition, the number of months since the patient's fIrst diagnosis of cancer was 




The age and sex of patients who did not return their questionnaire packs were recorded. 
It was also recorded whether they refused or agreed to involvement in a subsequent 
clinical trial. 
Dependent Variables 
Hypothetical Trial Scenarios (Appendix V) 
Previous research has used vignettes to assess patients' willingness to enter cancer 
clinical trials. However, the validity of these as a measure of whether or not patients 
will enter a trial has not been assessed. Research has indicated that most patients state 
that they would enter a trial, but statistically this is unlikely. No previous research has 
directly compared a patient's hypothetical decision with their real one. In this research 
vignettes were formulated to look at the correspondence between hypothetical choice 
and real choice. 
Four descriptions of trials were developed through discussions with a Consultant 
Oncologist. The participant was told that these are possible situations sometimes faced 
by patients. They were asked to read each one and indicate how likely they would be to 
enter the trial on a 5-point Likert scale ranging from 'defmitely agree' to 'defmitely not 
agree'. 
Triall. Focused on the situation where the standard treatment would not help. There 
was a new drug, which was randomized against placebo. 
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Trial 2. Focused on the new trial drug having more side-effects than the standard 
treatment. 
Trial 3. Focused on the new trial drug having fewer side effects than the standard 
treatment. 
Trial 4. Focused on the situation where there was no right or wrong treatment for the 
disease and two similarly effective treatments were included in the trial. 
A score of 1 to 5 was obtained on each hypothetical trial. These scores were combined 
to give an overall 'willingness to participate' score, (the higher the score the less willing 
the patient was to enter the trials). Comparison ofresponses on the individual trials was 
expected to reveal the importance patients attached to side effects, the possibility of 
receiving no treatment (placebo) and differences in predicted effectiveness. 
Research has indicated that relatives are an important source of support for cancer 
J 
patients and that when considering a trial, patients consult with their relatives. As 
patients are unlikely to make their decision in isolation, this research aimed to assess the 
impact of relatives' views. Therefore, the chosen relative was also asked to complete a 
copy of the hypothetical trials measure (see Appendix XIV). They were asked to 
indicate whether they thought their relative should enter the trials on the same 5-point 
Likert scales. Their scores were combined to give a 'relative's willingness to 
participate'score. 
Attitudes to Trials and Research Questionnaire (Appendix VI) 
The questionnaire was designed as a general measure of prior general attitudes towards 
medical research and cancer clinical trials. It addressed issues such as randomization, 
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double-blind trials, hope, chance of survival, benefit to others and the necessity of trials. 
This was included as authors have previously suggested that patients have biases 
towards clinical trials, and that patients make their decision based on these biases (e.g. 
Bujorian, 1988). Previously, research has not systematically addressed the impact of 
prior attitudes on a patient's decision about involvement in a subsequent clinical trial. 
This research aimed to compare patients' reported attitudes with their decision 
regarding a subsequent trial, and their expressed 'willingness to enter' the hypothetical 
trials. 
The I3-item attitudes questionnaire was developed through reviewing the literature, 
discussions with the academic supervisor of the research, and through a research 
presentation and discussion with other postgraduate clinical psychology trainees. 
Questions 1-10 focused on the issues noted above and patients were asked to indicate 
their responses on 5-point Likert scales. Lower scores indicated more positive attitudes 
to the value of clinical trial research. Scores from items 1-10 were combined to give an 
'attitudes total score' . 
Questions 11-13 considered the issues of who should make the decision to enter a trial 
and the influence of family members. These three items were not used in the 'attitudes 
total score', as they reflected n~ither a positive or negative attitude to trial research. 
Responses to these questions were considered independently. 
The participating relative was also asked to complete the 'attitudes to trials and research 
questionnaire'. The relatives' version took the same format and questions were the 
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same, except for wording changes to questions 9-12 (see Appendix XV). These were 
changed to ask the relative to consider how they felt aJx>ut the patient's participation, 
rather than their own. The relative was asked to complete this questionnaire as part of 
the exploration of the impact of their views on the patient's decision-making. 
Again questions 1-10 were combined to give an 'attitudes total score'. This was 
compared with the total score obtained by the patient. 
Hospital Anxiety and Depression Scale (HADS) 
(Zigmond and Snaith, 1983) (Appendix VII) 
As described in Chapter One, depression and anxiety are common in cancer patients 
(McDaniel et aI., 1995), and have been shown to influence response to chemotherapy 
(Walker et aI., 1999). The mood status of patients who enter clinical trials versus those 
who refuse may have implications for the outcome and generalizability of the trial. 
Previous research has not assessed these patients on a measure of anxiety and 
depression. 
The HADS was designed specifically for physically ill patients in the United Kingdom. 
Somatic items that are frequently associated with cancer are omitted so they do not 
affect the depression scores. It provides a measure of anxiety and depression and 
information on the clinical significance of the scores. This 14-item test asks patients to 
consider how they have been feeling over the last week and to rate statements that 
reflect common symptoms of anxiety and depression. The validity and reliability of this 
test for cancer patients have been demonstrated by many studies (e.g. Razavi et aI., 
1990; Grassi et aI., 1993). Moorey et aI. (1991) reported the internal consistency of the 
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two subscales as assessed by Cronbach's alpha to be 0.90 for depression and 0.93 for 
anxiety. Zigmond and Snaith (1983) assessed concurrent validity by comparison of 
HADS scores with 5-point psychiatric rating scales for 100 medical outpatients. The 
correlation coefficients were: anxiety r= 0.54, and depression r= 0.79. The scale takes 
approximately ten minutes to complete. 
Eysenck Personality Questionnaire - Revised Short Form 
(Eysenck and Eysenck, 1991) (Appendix VIII) 
A number of studies have investigated the relationship between personality and 
treatment response and survival in cancer (e.g. Ratcliffe et al. 1995). Again, previously 
the impact of personality on patients' decision-making about a clinical trial has not been 
investigated. 
The Eysenck Personality Scales attempt to measure the major dimensions of personality 
- P (psychoticism), N (neuroticism), E (extraversion) and L (lie scale or social 
conformity). Various earlier personality questionnaires were developed to form the 
EPQ, which has since been revised. A short scale was devised to save time, which 
includes 12 items from each of the four dimensions listed above. The EPQ manual 
(Eysenck and Eysenck, 1991) provides full statistical details of the scale. Reliabilities 
for the 4 scales are shown as; P, 0.62; E,0.88; N,0.84 and L, 0.77 for males. Similar 
figures are quoted for females. 
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Multidimensional Health Locus of Control Scale 
(Wallston et al., 1978) (Appendix IX) 
Research has suggested that patients with a high external locus of control are more 
likely to enter clinical trials (e.g. Verheggen et aI., 1998). However, this is an 
inconsistent rmding which requires further research to confirm differences between 
patients who consent and those who refuse clinical trials. 
This MDHLC scale provides a measure of three dimensions of health locus of control: 
Internality, the extent to which a person believes they have control of their own health, 
Chance, a measure of belief in external or chance factors determining their health, and 
Powerful Others, a measure ofbeliefthat others, particularly health professionals, have 
control over their health. 
There are 18 items on the scale, which the person must rate on a 6-point Likert scale 
ranging from 'strongly disagree' to 'strongly agree'. Each of the three scales are scored 
between 6 and 36. The scale takes approximately 5 minutes to complete. 
Wallston et aI. (1978) believed that a person's beliefs about personal control affect the 
decisions they make about their health. A person who scores highly on Internality is 
more likely to regard their health as within their control. 
The alpha reliabilities for each of the three scales ranged from 0.673 to 0.767 (Wallston 
et aI., 1978). Internality and powerful others were statistically independent, internality 
and chance were negatively correlated and powerful others and chance were positively 
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correlated. Health status was positively associated with internality, negatively 
associated with chance and was not related to powerful others. 
Courtauld Emotional Control Scale (CECS) 
(Watson and Greer, 1983) (Appendix X) 
The suppression of negative emotions has been suggested as a focal characteristic of the 
cancer-prone personality. Emotional expression has been associated in survival by 
some writers (e.g. Greer, 1991), and thus differences in emotional expressiveness 
between patients who consent to a trial and those who refuse may have important 
implications. 
The CEC is a questionnaire measure of the extent to which patients suppress negative 
emotions or show emotional control. There are three sections corresponding to the three 
moods: anger, anxiety and depression. In each section there are seven statements which 
the respondent must rate on a 1-4 point scale of frequency. 
Adequate test-retest reliability has been shown (anger 0.86, depression 0.89, anxiety 
0.84 and total score 0.95) and internal consistency (alpha coefficients 0.86, 0.88 and 
0.88). All three sections show significant positive correlations with each other, 
providing evidence for the validity of the scale as a measure of the emotional control 
construct (Watson and Greer, 1983). 
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Qualitative Measures 
Semi-Structured Interview Questions 
(Appendix XVI) 
Qualitative methodology has been suggested by other writers as the way to access 
patients' true feelings and experiences of cancer clinical trials (e.g. Cox 1998). The 
open-ended questions for the follow-up interviews were developed through discussions 
with a trials nurse, oncologists and a researcher who has previously conducted a number 
of qualitative studies on patients' experiences of cancer clinical trials. The questions 
were not designed to explore patients' trial experiences, rather they aimed to 
retrospectively investigate the decision-making process that the patient went through 
when the trial was proposed to them. They aimed to explore patients' attitudes before 
the trial and whether these had changed, their hopes and fears, how they made their 
decision, the influence of their family and whether this research study had influenced 
their decision. It was recognised that by providing information about trials and making 
patients think about the possibility of being entered, they may have been more receptive 
when faced with the 'real' trial. 
2.5 Proced u re 
Ethical Approval 
The Local Research Ethics Committee granted ethical approval for the project in July 
2000. The Research and Development Consortium also granted local trust approval 
before data collection began. 
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Recruitment 
Referrals between November 2000 and April 2001 were screened by the Consultant 
Oncologist. One NHS trust area in the North of England was used. Patients who were 
eligible for current phase I, II or III clinical trials were identified. Names were passed 
to the trials nurse who dispatched a pack containing the patient information sheet, 
consent form, attitudes questionnaire, hypothetical trial scenarios, HADS, EPQ-Short 
Form, MDHLC and the CECS (see Appendices II-X). The pack also contained the 
relative's questionnaires (see Appendices XI-XV) and a prepaid envelope for return. 
Completion and return of the packs was completely voluntary. 
The patient information sheet (see Appendix II) described the purpose of the study, why 
the patient had been chosen and a brief description of the nature of clinical trials. This 
description was included after 4 exploratory interviews revealed that patients were not 
sure what was meant by 'a clinical trial'. It was stressed that the study was not asking 
patients to enter a tria4 rather it was an investigation of their views. The information 
sheet also emphasised that participation was voluntary and separate to patients' medical 
care. The consultant would not be contacted about their results and all the information 
was confidential Instructions for filling in the pack and its return were included and it 
was stated that the patients would be contacted again in 3 months to participate in a 
further interview. It was emphasised that the patient did not have to agree to the second 
interview. 
If the questionnaires were not returned in 10 days, the trials nurse was consulted about 
the medical status of the patient. If the patient was deemed 'well enough' by the trials 
nurse a telephone call was made to the patient asking them if they had received the 
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questionnaire pack. Patients who had, but did not wish to return them were asked if 
they were willing to give a reason for this. Patients who did intend to return them were 
asked to do so as soon as possible. All patients were thanked for their time. 
A patient's decision regarding the cancer treatment trial offered to them was recorded. 
Ifa patient had entered a trial, the name of that that trial was recorded. This information 
was obtained from the clinical trials nurse. 
Follow-up Interviews 
The trials nurse was consulted before any attempt was made to contact patients again. 
Those who had died, were currently in-patients or were deemed too ill to participate, 
were excluded from the follow-up sample. Of the remaining patients, telephone contact 
was made with those who had volunteered for this study after 3 cycles of their 
treatment. They were asked if the researcher could visit them at home, or arrange to 
meet them at the oncology outpatient clinic for an interview. It was explained that the 
interview would take 45 minutes to 1 hour and was about how they decided to enter the 
trial and their experiences. It was again stressed that this was purely voluntary and they 
were under no obligation to agree. 
The patients who agreed were visited within the following week at a time convenient to 
the patient. The original patient information sheet was given again to patients and 
attention was drawn to the researcher's name and the person to contact for further 
information. Patients were reminded that they did not have to answer any questions if 
they did not wish to and that they could withdraw from the interview at any time. 
Interviews were recorded using a dictaphone. 
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2.6 Statistical Analysis 
The data were analysed using SPSS for Windows Version 9.0. The research supervisor 
and a statistician were consulted for advice on appropriate statistical analyses. Due to 
the nature of the data collected an exploratory approach was taken. The following 
analyses were conducted: 
• To assess the appropriateness of parametric or non-parametric analysis, the 
distribution of the variables were examined and the normality of the distributions were 
tested using the Kolmogorov-Smirnov test. 
• A Hierarchical Cluster Analysis was performed on the attitudes questionnaire to 
identify groups of questions measuring different themes. 
• A Hierarchical Cluster Analysis was performed on the attitudes questionnaire to 
identify particular groups of patients with similar views. 
• The clusters identified by the second Hierarchical Cluster Analysis were used as 
independent variables. Independent T-Tests were performed on the normally 
distributed dependent variables. The Mann-Whitney U Test was used to analyse the 
dependent variables that were not normally distributed. 
• A series of four questions were formulated in reference to the literature review 
and the data set investigated using appropriate statistical analyses for each. 
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• Content analysis was performed on the qualitative interview data. A second 
rater also completed the analysis. 
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CHAPTER THREE: RESULTS 
3.1 Recruitment 
During the data collection period from 14.11.00 to 20.04.01, forty-nine referrals of 
patients eligible for current phase I, II or III clinical trials were received by the two 
oncologists participating in this study. Questionnaire packs were dispatched to all 
forty-nine and thirty-one were returned, giving a response rate of 63%. 
The distribution of the eligible participants over the data collection period was 
examined and is shown in table 1. The number of patients eligible for trials ranged 
from 4 to 12 per month. The fewest number of questionnaires were dispatched during 
December and the Christmas period. This was also the time of the lowest response rate. 
As is shown below the response rate ranged from 100 to 50 %. 
Table 1: Questionnaire packs sent and returned during November 2000 - April 
2001 
Month Questionnaires Sent Questionnaires Returned (%) 
November 12 7 (58) 
December 4 2 (50) 
January 6 6 (100) 
February 9 5 (55) 
March 12 8 (66) 
April 6 3 (50) 
Total 49 31 (63) 
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All (100%) of the participants (patients who returned their questionnaires) consented to 
the clinical trial proposed to them. Table 2 shows the relative rates of trial consent of 
the participants and non-responders (patients who did not return the questionnaires). 














Only 2 of 49 patients (4.1%) refused clinical trial participation and both did not return 
their questionnaires. 
An examination of the trials to which participants consented revealed that there were 9 
current cancer chemotherapy clinical trials. These were grouped according to the phase 
of the trial (I, II or Ill). The number of participants in each phase of trial is shown in 
table 3. Data were unavailable on 3 participants. 
Table 3: Participant consent to trials by phase 
Phase Number of Participants (%) 
I 8 (28.5) 
II 12 (43.0) 
III 8 (28.5) 
Total 28 (lOO.O) 
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3.2 Comparison of Participants and Non-Responders 
The age and sex of the non-responder and participant groups are show below in table 4. 
Statistical analyses showed that the groups were not statistically different on these 
variables. It was not considered ethically acceptable to consult records for further 
demographic information on the non-responder group. 
Sex 
Approximately equal numbers of male and female patients participated in this study. In 
comparison, it was noted that a high proportion of males existed in the non-responder 
group. However, Chi-Square analysis found no association between sex and whether or 
not a patient participated in this research (Chi-Square=2.0, df=I, p=0.157). Fisher's 
Exact Test was also not significant (p=0.23). 
Age 
The mean age of the participant group was 59.5 years (SO 10.1). The male participants 
had a mean age of 64.6 years (SO 8.5) and the females were younger by a mean of 10.4 
years. The non-responder group was slightly older than the participant group, although 
this difference was not statistically significant (t=-0.342, df=47, p= 0.734). 
Table 4: Comparison of age and sex of participants and non-responders 
n Mean Age Mean Age 
(SOl (SD) 
Males 16 64.6(8.5) 
Participants 59.5(10.1) 
(N=31) Females 15 54.1(9.1) 
Non- Males 13 60.0(15.0) 
responders 60.7(13.7) 
(N=I8) Females 5 62.6(10.85) 
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3.3 Demographics of Participants 
Marital Status 
As shown below 77.4% of the sample were married and 12.9 % divorced. A minority 
was single or widowed. 
Table 5: Marital status of participants 
Marital Status Frequency Percentage 
Married 24 77.4 
Divorced 4 12.9 
Single 2 6.5 
Widowed 1 3.2 
Total 31 100.0 
Education 
The majority (48.4%) of the sample had completed education to the secondary level. A 
considerable proportion (35.5%) had education at the college level and 5 participants 
had been to university. 
Table 6: Education completed by participants 
Frequency Percentage 
Secondary 15 48.4 
Further 11 35.5 
Graduate 3 9.7 
Post -Graduate 2 6.4 
Total 31 100.0 
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Occupation 
The occupations of participants were recorded as: 1 = professiona4 2= skilled, 3= semi-
skilled, 4= unskilled manual. If a participant was retired they were classified according 
to their previous occupation and if they were a 'housewife' they were classified 
according to their spouse's occupation. Nearly half the sample were unskilled workers, 
16.1 % were semi-skilled, 29% were skilled and a minority were in a professional 
occupation (see table 7). 



















Only three participants indicated that they had suffered additional, difficult life events in 
the last 6 months. All three noted fmancial difficulties, which were related to being 
unable to work. 
3.4 Information on Disease 
A count of the number of months since a participant's first diagnosis of cancer was 
made. The total number of times a cancer had been diagnosed on different occasions 
and the total number of treatment courses participants had been given (included 
surgical, radiotherapy and chemotherapy) were recorded. It was noted whether or not a 
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participant had enrolled in previous cancer clinical trials. The number of months since 
the diagnosis of the most recent cancer was recorded. The medical files of two 
participants could not be recovered. 
Time since first diagnosis 
There was a range of 180 months (15 years) in the time since participants' flrst 
diagnosis of a cancer. Hence, some were newly diagnosed with a primary cancer and 
others experienced reoccurring disease. The results are shown in table 8. 












Participants had been diagnosed with cancer between one and four times (inclusive of 
the cancer for which they were referred for the trial). The mean number of diagnoses 
was 1.93 (SD 1.1). Table 9 shows the frequency of the number of diagnoses. It can be 
seen that nearly half of the sample had been diagnosed with cancer for the first time. 
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Five (17.9%) of the participants had not received any previous treatments for cancer. 
The modal number of previous treatments was 2. Therefore, although nearly half the 
sample had been diagnosed with only one cancer, many participants had received 
previous treatments. The frequencies are shown in figure 1. 









Number of previous treatments 
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Std . Dev = 1.66 
Mean = 2.1 
N = 29.00 
Time since most recent diagnosis 
It is shown in figure 2 that approximately half the sample had been diagnosed with their 
most recent cancer (for which they were offered the trial) within the previous month. 
The mean time since diagnosis was 2.2 months (SD 3.7). 













3 5 7 9 11 13 15 
o 2 4 6 8 10 12 14 16 
Months since most recent diagnosis 
Previous cancer clinical trials 
Std . Dev = 3.73 
Mean = 2 
N = 29.00 
None of the 29 participants had previously been treated in a cancer clinical trial. 
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3.5 Psychometric Measures 
The mean scores and standard deviations on each of the standardized psychometric 
scales are shown below in table 10. It can be seen that that some questionnaires were 
omitted by participants. The data on the HADS showed that the sample was not 
significantly depressed or anxious. The results from the psychometric scales are 
discussed in later sections. 
Table 10: Mean scores of the participants on the psychometric measures 
Measure n Min. Max. Mean St. 
Score Score Score Deviation 
HADS - Anxiety 29 2.00 14.00 6.76 3.0 
HADS - Depression 29 1.00 14.00 5.31 3.23 
EPQ-P 31 0.00 9.00 2.42 1.88 
EPQ-N 31 0.00 12.00 5.06 3.08 
EPQ-E 31 0.00 12.00 7.26 3.45 
EPQ-L 31 1.00 11.00 5.74 3.16 
MDHLC -Internal 30 11.00 33.00 21.63 5.72 
MDHLC-Chance 30 13.00 14.00 20.03 5.07 
MDHLC-Powerful 30 7.00 32.00 19.27 6.95 
Others 
CEC-Angry 25 7.00 20.00 14.10 3.84 
CEC- Unhappy 25 8.00 22.00 17.04 3.02 
CEC-Anxious 25 12.00 23.00 17.72 2.98 
CEC-Total 25 34.00 64.00 49.16 7.28 
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3.6 Demographic Information on Relatives 
Twenty-eight relatives completed and returned the questionnaires. Their mean age was 
similar to that of the patient sample. 
Table 11: Age oCrelatives 
Minimum Maximum Mean St. Deviation 
N=28 24.00 85.00 55.6071 13.5874 
Relationship to patient 
The majority of the participants chose their spouses to complete the questionnaires. A 
few chose a brother or daughter and only one participant chose to ask a friend (see table 
12). 
Table 12: Relationship of relative group to patient participants 
Relationship Frequency Percentage 
Partner I 3.6 
Husband 12 42.9 
Wife 9 32.1 
Brother 2 7.1 
Daughter 2 7.1 
Niece 1 3.6 
Friend I 3.6 
Total 28 100.0 
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3.7 Statistical Analysis 
As is shown above all the participants consented to a clinical trial. Hence, the data 
could not be divided into two groups according to consent or refusal of a trial, as 
described in Chapter 2: Methodology. As it was not possible to use the data obtained to 
test the hypotheses, an exploratory approach to the data was taken. 
Distribution of data 
The distribution of the raw data of each of the dependent variables was examined. The 
Kolmogorov-Smirnov test was used to test the deviation from normality of each 
distribution. 
The K-S tests for the attitudes total score, age, HAnS anxiety, EPQ-E, EPQ-N, 
MDHLC internal, MDHLC powerful others, CEC-Angry, CEC-Anxious, and the CEC-
Total score were not significant indicating that the distributions were normal. 
A mathematical square root function was applied to the HAnS depression scores, the 
hypothetical trial total scores, the EPQ-Lie scale scores and the CEC-Unhappy scores. 
After the application of this function, The K-S tests were not significant, indicating that 
the distributions were normal. The square root functions were used in the statistical 
analyses. 
The K-S tests for the attitudes questions 1-13, the hypothetical trials 1-4, the MDHLC-
Chance scale and the EPQ-P scale were significant, indicating that the distributions 
were not normal. The distributions for the attitudes questions 7 and 11 were negatively 
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skewed. All the other distributions that were not normal were positively skewed. 
Exploratory analysis of the attitudes questionnaire 
Advice from a statistician was taken and a hierarchical cluster analysis was performed 
on the attitudes questionnaire (Appendix VI) to identify relationships between the 
question items. This measure was selected as it was considered to cover a wide range of 
aspects of trials and medical research, as opposed to the hypothetical trials, which were 
more constrained in their focus. As this was a new measure it was unknown whether it 
measured a single underlying construct or a number of different ones. Questions I to 10 
were used in the analysis as these used the same scale. Questions 11 to 13 were 
excluded, as their scales did not range from positive to negative. This test does not rely 
on the normal distribution of the data. The results of the hierarchical cluster analysis are 
shown below in Figure 3. 
Figure 3: Dendrogram using average linkage (between groups) 
Rescaled Distance Cluster Combine 
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The analysis showed a close relationship between questions 1,2 and 3. Examination of 
these questions (see Appendix VI) showed that they all referred to the potential benefit 
of research and clinical trials. 
Questions 6 and 7 were also closely linked and these questions referred to prolonging 
life. Interestingly, question 4, which referred to the cure of cancer, was not closely 
linked to these items by the analysis. 
Questions 5, 9 and 4 were linked by the analysis. It was more difficult to see the 
connection between these questions as they dealt with randomization, cure and whether 
or not patients should vo lunteer for research. 
Overall, questions 1 down to 4 on the dendrogram were clustered together in one main 
group. Hence, the hierarchical cluster analysis of the attitudes questionnaire suggested 
that the majority of the questions were measuring the same construct. 
It also identified two questions (8 and 10) that were separate from this main cluster, but 
not linked together. Question 10 addressed a patient's views on double-blind 
methodology and question 8 asked whether patients received more help and support in a 
clinical trial. Participants' attitudes to these issues were shown to be different from 
their attitudes to the other questions. 
Exploratory analysis of participants' attitudes 
Advice from a statistician was taken and a second hierarchical cluster analysis was 
performed on the attitudes questionnaire with the aim of identifying particular groups of 
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participants within the trial group. Therefore, this time the test clustered cases 
(participants) rather than variables (questions). Figure 4 shows the dendrogram results 
from the cluster analysis of the participants. 
Figure 4: Dendrogram using average linkage (between groups) 
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An examination of the dendrogram identified two main .clusters and one outlier. The 
first cluster is shown from participant number 13 to 31 (23 participants), the second 
from number 8 to 9 (6 participants) and the outlier is number 15. 
The raw data from these groups were examined. Participant 15 emerged as having 
higher scores on the attitudes questions, indicating less positive views. The participant 
indicated that she was 'very uncomfortable' with randomization and double-blind 
methodology. This response was unique to her case in this study. The patient also 
indicated strongly that it was her choice and that the doctor was not the best person to 
decide. The participant felt ambivalent as to whether participation in a trial would help 
future patients and disagreed that a 'miracle' cure would be found. 
Cluster 1 
In comparison, the largest cluster of participants showed positive views towards trials 
and research. Their responses were generally more mixed and less positive than the 
second cluster described below. Their responses indicated that they agreed that the trial 
would help future patients, that patients should volunteer, and that a cure would be 
found. The participants in this cluster were most likely to indicate that they were 
'neither uncomfortable nor comfortable' with randomization and double-blind 
methodology. Half the group thought the doctor was the best person to make the fmal 
decision, five more were ambivalent about this statement and the remaining six 
disagreed with the statement. 
Cluster 2 
The second cluster of six participants formed a highly positive group. They indicated 
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very positive attitudes to entering trials, strongly agreed that a trial would help others, 
that patients should volunteer, and that a cure would be found. All the participants in 
this cluster indicated they would be 'very comfortable' or 'somewhat comfortable' with 
randomization and double-blind methodology. Entering the trial would give this group 
'a little' or 'a lot' more hope than receiving the standard treatment. All but one 
'strongly agreed' that the doctor was the best person to make the fmal decision. They 
perceived themselves as having less choice than cluster 1 when asked to enter a trial. 
Analysis of cluster differences 
For the purpose of further analysis, the two main clusters were considered to be two 
independent, unrelated groups, on the basis of their attitudes to clinical trials. 
Independent T-Tests were performed using the two main cluster groups to test the 
difference in means on the dependent variables. For all but one of these variables, 
Levene's test for equality of variances was not significant, indicating that the variances 
in the two groups were equal. The results of the effect of cluster on the dependent 
variables that met the parametric assumptions are shown in table 13. 
Some participants did not complete all of the questionnaires. Consequently, scores from 
the HADS (2 participants), MDHLC (1 participant) and CEC (5 participants) were 
missing from cluster 1. The CEC scores were missing from 1 participant in cluster 2. 
It is shown that just one result was statistically significant; the difference between the 
hypothetical trial scores. An examination of the data showed that cluster 1 had a higher 
mean hypothetical trial total score. This indicated less Willingness to enter the trials 
than cluster 2. Hence, cluster 2, who had highly positive attitudes, had significantly 
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lower (more willing to enter) hypothetical trial scores. 
The EPQ-Neuroticism score approached significance (p=O.077). The second, highly 
positive cluster had higher EPQ-N scores, suggesting a relationship between attitudes 
and scores on this measure. 
Table 13: Independent T -Test results 
Variable t df Mean Significance 
Difference (2-tailed) 




-anxiety 0.147 25 0.214 0.884 
-Depression -0.129 25 -4.39 0.898 
EPQ: 
-E 0.385 27 0.377 0.703 
-N -1.840 27 
-2.558 0.077 
-L 0.326 27 0.106 0.747 
MDHLC: 
- Internal -0.591 26 -1.515 0.559 
- Powerful others -0.848 26 -2.742 0.404 
CEC: 
-Angry 1.017 21 2.011 0.321 
-Anxious 1.261 21 1.789 0.221 
-Unhappy· 1.450 20.399 1.456 0.162 
-Total -0.619 21 
-2.344 0.543 
• Equal variances not asswned 
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It should be noted, that by carrying out 12 independent t-tests the probability of at least 
one Type-I error is greatly increased to 49%. In this case the Bonferroni Correction 
should be considered. When applied, this shows that significance should only be 
accepted when less than 0.0042. This correction has been criticised for being too 
conservative and hence increasing the probability of a Type-II error. However, the 
significant difference found should be interpreted with caution and not considered 
rigorous. 
The Mann-Whitney U Test was used to assess differences between the two clusters on 
the cancer-related information, years of education and EPQ-P scores. This non-
parametric test was selected as the distributions of these variables deviated significantly 
from normal according to the K-S test. The results of the Mann Whitney U Test are 
shown below in table 14. 
Again, some data were missing. In cluster 1, one participants' MDHLC chance score 
was missing and the disease related information was not available on 2 participants. 
Otherwise the data set was complete. 
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Table 14: Results orMann Whitney U Analysis 
Variable Mean Rank Mean Rank Mann WhitneyU Sig. 
cluster 1 cluster 2 
Months since 
First diagnosis 14.23 11.08 45.5 0.376 
Months since 13.00 15.17 50.0 0.457 
this diagnosis 
Number 
diagnoses 13.88 12.25 52.5 0.622 
Number 13.57 13.25 58.5 0.926 
treatments 
Years 15.83 11.83 50.0 0.297 
education 
EPQ-P 14.50 16.92 57.5 0.527 
MDHLC 13.95 16.50 54.0 0.499 
-Chance 
The differences between the two clusters on these dependent variables were not 
statistically significant. It should be considered that by using a non-parametric test the 
probability of a type II error has been increased due to reduced statistical power. The 
two clusters show a mean difference of23 months (but only 3.15 ranks) on the 'time 
since first diagnosis' variable. This may suggest that a longer length of disease (cluster 
1) leads to less positive attitudes. However this difference was not statistically 
significant according to the Mann Whitney U Test. 
The increased probability of a type II error needs to be balanced again against the 
increased probability of a Type I error caused by using 7 Mann Whitney U Tests. 
Again, the Bonferroni Correction needs to be considered. 
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3.8 Further Exploratory Analyses 
A series of four questions were formulated with the aim of making exploratory analyses 
of the relationships between the variables. The four questions chosen were based on 
themes from the literature review and from the qualitative interviews. 
Question 1 
Does the number of previous treatments affect participants' attitudes? 
Spearman's Rho correlation coefficient was used as the data violated parametric 
assumptions. The correlation between number of treatments and participants' attitudes 
as measured by the attitudes total score was not statistically significant. The 
relationship is illustrated in figure 5. 
Figure 5: Scatterplot illustrating the relationship between number of previous 
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Question 2 
Are participants' scores on the attitudes questionnaire related to 'willingness to 
enter' as measured by the hypothetical trials? 
A statistically significant positive correlation was found between the attitudes score and 
participants' willingness to enter the hypothetical trials (Pearson=0.396, R 2=0.157, 
p=0.027). Participants with more positive views were more willing to enter the 
hypothetical trials. Figure 6 illustrates this relationship. However, the R2 value shows 
that only 15.7% of the variance in hypothetical trial scores can be accounted for by the 
attitudes score. 
Figure 6: Scatterplot illustrating the relationship between attitudes and willingness 
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Question 3 
Is a participant's perception of choice related to personality and locus of control 
measures? 
For the purpose of this analysis participants were divided into three groups according to 
their responses to question lion the attitudes questionnaire: " If my doctor asked me to 
participate in a clinical trial, I would feel I had no other choice". The groups were as 
follows: 
Group 1 (n=6) : Participants who indicated that they 'strongly agree' or 'agree', 
Group 2 (n=7) : Participants who indicated that they 'neither agree' or 'disagree', 
Group 3(n=17): Participants who indicated that they 'strongly disagree' or 
'disagree' . 
This question was chosen as a measure of 'choice' as it was considered to reflect the 
patient's perception of a doctor offering them a clinical trial. It was considered to be a 
measure of the how much the patient would feel pressurised and whether they could see 
the possibility of alternatives. The concept of 'choice' is a very complex variable and 
this is only a very narrow and limited measure of this. 
One way analysis of variance was used for the variables that met parametric 
assumptions. The Kruskall Wallis test was used for the remaining variables. 
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Personality (Eysenck Personality Questionnaire, EPQ) 
One way analysis of variance found a statistically significant effect of ' choice ' on the 
EPQ - Neuroticism scale (F=3.683, df-=2,27, p=<O.05). Figure 7 shows the mean EPQ-
N scores with 95% confidence intervals for each of the choice groups. It is shown that 
group 1, who perceived themselves as having the least choice if asked to enter a trial, 
had the highest EPQ-N scores. Group 3, who saw themselves as having the most 
choice, had the lowest EPQ-N scores. Group 2, who neither agreed nor disagreed with 
the statement, had a mean EPQ-N score that fell in between the two other groups. 
Figure 7: Mean and 95% confidence intervals of EPQ-Neuroticism scale scores for 

















A significant effect of choice was found on the EPQ-Psychoticism scale usmg the 
Kruskal Wallis test (Chi-Square= 8.451 , df=2, p=<O.05). Figure 8 shows the mean 
EPQ-P scores with 95% confidence intervals for each of the choice groups. Group 3 
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(highest perception of choice) is shown to have the lowest EPQ-P scores. Groups 1 and 
2 have similar mean scores, but group 2 has a larger range within 95% confidence 
interval of the mean. 
Figure 8: Mean and 95% confidence intervals of EPQ-Psychoticism scales scores 
















Choice did not have a significant effect on the EPQ-Extraversion or EPQ- Lie scales. 
Locus of Control (Multidimensional Health Locus of Control cale, MDHLC) 
A statistically significant effect of choice on the Internal scale of the MDHLC was 
found (F=3.412, df-=2,26, p=<O.05), and on the Powerful Others scale (F=7.989, 
df-=2,26, p=<O.005). 
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Figure 9 shows that group 1 (lowest perception of choice) had the highest scores on the 
Internal locus of control scale. In general, as perception of choice increased, scores on 
the Internal scale decreased (locus of control became more external). 
Figure 9: Mean and 95% confidence intervals ofMDHLC Internal scale scores for 





















Figure 10 shows the mean and 95% confidence intervals for the MDHLC Powerful 
Others scales. It is shown that as perception of choice increased over the three groups 
the scores on the Powerful Others scale deceased. 
Choice was found not to significantly affect scores on the Chance scale of the MDHLC 
using the Kruskal Wallis test (Chi-Square= 5.061, df=2, p=0.08). 
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Figure 10: Mean and 95% confidence intervals ofMDHLC Powerful Others scale 
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Question 4 
Are participants' and their relatives' attitudes and willingness to enter trials scores 
related? 
The majority (96.7%) of participants indicated that they would take into account the 
views of their family in response to Question 12 ("If you were asked to participate in a 
clinical trial how much would you take the views of your family/friends into account"). 
Thus, this population's views were considered important. Table 15 hows the mean 
total attitudes score and the mean total hypothetical trials score of the participant and 
relative groups. Only those participants who had a relative who completed the 
questionnaires were included. 
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Table 15: Mean attitudes total score and hypothetical trial total score for 









Mean (SD) hypothetical 
trials total score 
7.39 (2.1) 
7.25 (2.41) 
It is shown that the scores for the two groups were very similar. Pearson Correlation 
was used to examine the relationship between each participant and their chosen 
relative's views. The correlation coefficients on both the measures were not significant. 
Therefore, while the two groups were similar in their views, this was not so on a case by 
case basis. 
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3.9 Qualitative Findings 
A convenience sample of the fIrst four participants to complete three cycles of treatment 
during February 2001, who were considered physically well enough by the trials nurse, 
were approached for interview. All four agreed and were visited by the researcher at 
their homes. The sample consisted of one male and three females. The mean age of the 
sample was 56.5 years (SD 11.1). 
Content Analysis was performed on the semi-structured interview data. Three main 
categories were pre-determined in the analysis as these were the focus of the original 
interview questions. As the questions would have influenced the participants' 
responses, it was felt artifIcial to claim that these emerged from the data. The categories 
were Attitudes, Decision-Making and Diseaserrreatment Experiences. In each of these, 
further sub-categories emerged from the data. 
A second person was also asked to perfonn the analysis. The second rater was a male 
non-psychologist, with a background in special education teaching and previous 
experience of using qualitative methods. He was not familiar with the background 
literature or aims of this study. The second rater's categories differed from the fIrst 
rater. The second rater identifIed main emotional and behavioural themes. In contrast, 
the fIrst rater focused more on the trial process. The second rater's themes were 
considered to run through the sub-categories identifIed by the fIrst rater. The themes are 






All four participants in this study reported holding positive views towards medical 
research in the past. They described it as "a good way of fmding new treatments" and it 
being needed in society. 
More specifically, when asked about clinical trials participants remained positive in 
their opinions. Three of the participants had been involved in some form of research in 
the past. However, they did not draw a distinction between chemotherapy clinical trials, 
newly available tried treatments, and their x-rays being shown to medical students. To 
the participants the basis of 'research' was common to all of these and they felt 
comfortable with it. 
One of the participants had no previous experience of clinical trials or medical research. 
He described how it was "all new to me", but nevertheless he still thought he held a 
positive view of such treatments. He believed that he had a limited understanding of 
clinical trials before being asked to enter one, and that he was still unclear about many 
issues. 
Impact of this research project 
Three out of the four participants could remember reading the information and filling in 
the questionnaires. However, they could not remember the actual questionnaires or 
their responses. One participant thought that the project had made her think more about 
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trials in a general sense. All four participants said that the research had not influenced 
their decision about the clinical trial. In general, the participants did not seem to have 
made a connection between the two. Two participants thought the hypothetical trial 






The theme of being interested in research and actively 
seeking information to aid understanding, e.g. via the 
Internet, was identified. Interest in this research project 
formed part of this information seeking theme. 
The theme of confusion about how the trial fitted into the 
wider picture of research and science emerged. Lack of 
understanding of trials and their purpose, and of the 
relevance of this project was found. 
2. DECISION-MAKING 
All participants could recall being asked about the trial and could give brief details 
about the protocol. All four knew that participation was voluntary and that they had a 
choice between saying yes or no. One participant knew there was no alternative 
treatment, but two didn't know what would have happened if they had said no. One 
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participant knew that she would be treated, but knew nothing of the alternative 
treatment. Consequently, all four felt there was no 'real choice': 
" I don't think there was an alternative. I don't seem to remember ... I was that shocked 
at the cancer ..... I didn't really listen to what he was saying, apart from the fact that 
there was this treatment that was a triaL .. I was more thinking of that than any other 
offer. " 
All participants described making their decision quickly, usually between 15 and 45 
minutes after ftrst being asked. One participant made her decision spontaneously, she 
said "it never entered my mind to say no". The participants expressed trust in the 
doctor and their expert opinion. After leaving the hospital all four discussed the trial 
with family members, mainly with the purpose of checking that they were comfortable 
with the treatment. For some family members it was "another road to go down" and 
they felt that ''there was nothing to lose". However, while participants wished to check 
out their family'S views, they also felt that no one could have changed their mind. 
Motivations 
Participants' reasons for entering the trial fell into the two main categories of 'helping 
themselves' and 'helping others in the future'. 
Helping themselves: The participants expressed the idea that the treatment would 
somehow do them good. It offered them hope for stopping tumour growth, prolonging 
life, but interestingly, not cure. None of the participants thought this trial would cure 
them. Two expressed having "nothing to lose" and: 
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"As long as it's not making me worse .... or feeding the complaints, I'm all right with it." 
For one participant, the fact that the treatment was experimental made it possibly a 
superior treatment: 
"With science and medical advances ... the trial is more up to date, and so has more 
hope in it. " 
Helping others in the future: participants expressed concern and pleasure that the 
research would be used to help others in the future. However, such altruistic motives 
were mentioned less than those pertaining to the participants' own lives. 
To all four participants it did not matter that the chemotherapy they were receiving was 
experimental. It was not an issue of importance to them. To them it was a treatment 
foremost and it offered the best hope of life. The choice to enter the trial was not a 
difficult decision to make for all four participants. One described it as "automatic". 
Another said: 
"If there's not much chance with the normal treatment, and they hope this is better, well 
that's it." 
This links with earlier descriptions of the lack of choice these participants felt they had 
realistically. 
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For one participant, being part of the trial fitted in with her self-concept as someone 
who helped others: 
"I'm doing a bit of good. I'm always doing things for other people. It's always for 
someone else ... this is just something else I have taken on." 
Barriers 
The four participants interviewed could not recall any particular worries about the trial. 
They seemed to have calmed any concerns they may have had with the knowledge that 
they could discontinue the trial at any point. This was a very important aspect for them: 
" ... You can stop treatment anytime you like, you are not forced to go ahead and have 
it. " 
"If it's not working they will change it, ... so I wasn't putting myself in a corner. " 
THEMES: 
Hope: 
Nothing to lose: 
The focus on positive aspects of the trial and what it offered to 
the participant emerged as an overall theme of this category. 
The theme of being forced by circumstances into the decision was 
identified. From the time ofproposal, to consulting with others, 
to making the decision, this factor was evident in participants' 
responses. 
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3. DISEASEffREATMENT EXPERIENCES 
SUB-CATEGORIES 
Impact of disease 
On diagnosis all participants described shock and horror that the cancer had returned or 
occurred: 
"Four years down the line, I thought I was OK. I only had a year to go, to get the all 
clear. You have the carpet ripped/rom under you." 
" .... He said 'cancer' straight away, well, it terrifies you. " 
Differences were evident between the participants when they were asked about how the 
cancer had changed their lives. One participant described ''making the most of each 
day" and striving to maintain as normal as life as possible. She had tried to continue to 
do the things she had before, even if she had to come home earlier or not travel as far. 
She thought that it hadn't changed her as a person: 
"We worry, naturally, but you don't let it get you down. " 
Another described in detail and with dismay the differences in his everyday life. These 
ranged from being unable to do domestic chores to not being well enough to go on 
holiday. For this man the cancer was something he did not deserve and it had 
devastated his plans for his retirement years. 
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Three of the participants thought that cancer had changed their personalities. One 
described becoming depressed and irritable, where as before she was an easy-going 
cheerful individual. One said: 
"I'm a different person altogether. I'm not me as I was before. Before I was bubbly. I 
can be nasty to my wife, she only has to make the slightest mistake. " 
Even within this small group, different responses emerged (both emotional and 
practical) to having cancer. 
Experience of clinical trial treatment 
All four participants described distressing physical side effects from the trial 
chemotherapy. All four said that they expected these and thought the effects would be 
similar in any non-experimental treatment. However, one participant mentioned feeling 
like a "guinea pig" at the start of her trial when she suffered severe side effects. Three 
of the participants had considered discontinuing the trial due to the side effects and at 
these times they called on relatives and professionals for help and advice. For these 
participants the hope that it would get easier helped them to continue. 
Three participants described changes to their life-style as a direct result of the treatment. 
Being too unwell to work, go on holiday or socialize were important losses for them. 
In retrospect, none of the participants felt they had any misconceptions about what the 
trial would be like. Likewise, none of their views and attitudes towards clinical research 
had been changed by the trial. All four participants said that they would volunteer for a 
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trial if given the choice again. Althoug~ one participant though she may decline if the 
trial involved "a lot of risk" in tenns of adverse effects. Again, the experimental nature 
of the treatment was not relevant to participants on a day to day basis. It was just a 
treatment. 
The future 
All the participants expressed hope and optimism that the trial chemotherapy was 
working and predicted (although tentatively) positive outcomes. One participant 
predicted that after the trial he would be feeling: 
uHopefully full of vigour. I'm having a scan in a month, I hope it shows it's shrinking. 
The pains gone, I don't think it's growing anymore. " 
All the participants were highly focused on their next scan which would tell them if the 
trial was having any effect on their disease. This was a point of great anticipation and 
anxiety. The success of the trial was the most important aspect of their future. 
THEMES: 
Anger and resentment: 
Worry: 
The theme of intense and distressing emotional reactions 
to participants' experiences was evident throughout this 
category. 
The theme of great concern about the impact of the 
disease and its treatment on health, relationships and 
quality of life emerged. 
102 
Moving on: The theme of actively coping with adversities, (e.g. using 
humour, support and recreation) and looking towards the 
future was found in this category 
Summary of Qualitative Findings 
The categories and themes identified in the analysis are shown in figure 11. Participants 
reported positive views of clinical trials and research, and that these had not been 
changed by their experiences. Their decision to enter the trial was not difficult and they 
did not consider refusing. They were unclear about the alternatives. To these four 
participants the trial was a treatment, first and foremost. They hoped it would help them 
to live longer, but thought it would probably not cure them. The diagnosis of cancer 
and having chemotherapy had changed the lives of all the participants. In the longer 
term, individual differences in coping were evident. All were hopeful for the future and 
did not regret entering the trial. 
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Figure 11: Main categories, sub-categories and themes identified by the analysis. 
Main categories Sub-categories Themes 
ATTITUDES Pre-held views Informat ion-seek ing 
Impact of this project Confusion 
DECISION-MAKING Trial Proposal f-lope 
Motivations Nothing to lose 
Barriers 
DISEASE/ Impact of disease Anger & Re entm nt 
TREATMENT Experience of trial treatment Worry 
EXPERIEN CES The future Moving n 
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CHAPTER FOUR: DISCUSSION 
4.1 Discussion of Main Findings 
The research found that 95.9% of eligible cancer patients consented to the 
chemotherapy clinical trial proposed to them. This is strikingly different from other 
recent studies. For example, Spiro et aI. (2000) found that only 26.5% of eligible 
patients consented to the triaL A review of the literature has found patient refusal as a 
reason for non-entry to range from 15 to 32% (Cook-Gotay, 1991). The apparent 
refusal rate of 4.1 % found in this research was highly unexpected. 
The possibility that patients who refused a trial may also refuse to take part in this 
research project was considered during the design phase of the project. However, the 
potential problem that so few would refuse trial entry was not foreseen. It must be 
questioned why such a high consent rate occurred on this occasion. 
The high rate of consent may be a characteristic of the oncology department studied. 
Increased accrual rates have been found in centres participating in national cancer 
programs (Cook-Gotay, 1991) and the centre used in this study was involved in a 
number of multi-centre trials. However, the original impetus of this research was the 
Head of Department's observation of a difficulty in recruiting eligible patients to 
clinical trials. During subsequent discussions the hospital appeared to be a typical 
example of a national problem. 
Another possible explanation was that this research influenced patients' decisions. By 
introducing the idea of a trial, patients may have been more open to further 
consideration, a phenomenon know in social psychology as the 'foot in the door effect' 
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(Synder & Cunningham, 1975). Indeed, the information sheet contained a paragraph 
explaining the nature of clinical trials (See Appendix II). This was included as 
preliminary discussions with patients revealed that they were unsure what a clinical trial 
was. If lack of understanding is a reason for refusal, this research may have influenced 
the accrual rate. While we know that patients have poor understanding and recall of the 
trial information provided (e.g. Casseilth et aI., 1980), no study has yet systematically 
investigated the role ofthis on clinical trial participation. It is therefore unclear whether 
or not this research influenced patients' decisions. 
This research may have made patients more likely to consent in a general, indirect way. 
Patients may have been less worried by the trial proposal as they had already been 
exposed to an information sheet, consent form and to the general process of research. 
Although it may be argued that this was a completely different type of research, the 
qualitative fmdings showed that participants considered research as a unitary concept 
and did not differentiate between different forms. Hence, exposure to 'research' may 
have influenced the consent rate. 
Other reasons for the high participation rate pertain to hospital influences. It may be 
that staff were more active in their recruiting, as they knew a research project was in 
progress. 
Characteristics of the trials and the eligible patients may have influenced the consent 
rate. Post hoc examination of the inclusion criteria for the clinical trials revealed that a 
number required patients with advanced or metastatic (secondary tumours at a distance 
from the primary site of cancer) disease. Some trials required patients who had 
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inoperable cancer or for whom ftrst line chemotherapy had failed. It is a possibility that 
the trials involved in this research required patients who had few alternatives and this 
caused the high consent rate. Previous research that has quoted lower consent rates 
may have focused on trials with different inclusion criteria. 
It is also a possibility that patient refusal is not the main problem in accruing eligible 
patients for trials at this centre or elsewhere. Less than 3% of cancer patients are 
estimated to receive treatment as part ofa clinical trial (Benson et aI., 1991). This study 
suggests that this is not due in the main to patient refusal and that low participation 
rates may be due to other factors. These include: patient ineligibility (e.g. Lee et al., 
1980; Lee & Breaux, 1983), lack of physician time and research staff (Smith & 
Goodare, 1995), patients' logistical reasons (Cook-Gotay, 1991), physicians' 
difficulties in obtaining informed consent (Taylor & Kelner, 1987a), physician 
reluctance to discuss controversies of treatment with patients (Taylor et at, 1984) and 
physicians' concerns about the impact of randomization on the doctor-patient 
relationship (Taylor & Kelner, 1987b). 
It is interesting that the two patients, who refused clinical trial participation, also chose 
not to consent to this research project. Cox (1999) has reported similar fmdings. 
Although conclusions cannot be drawn from only two patients, it may be the case that 
these patients are reluctant to take part in research in general, rather than just the 
clinical trial. They may hold negative views about research that extend beyond the 
clinical trial. This means that studies that aim to investigate the views of patients who 
refuse to enter clinical trials will have difficulty in accruing their sample. 
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Finally, it is also a possibility that the consent rate of 95.9% found by this research is 
not reliable, due to recruitment difficulties. This is discussed later in section 4.2. 
The hypotheses and planned statistical analyses aimed to compare patients who refused 
with those who consented. All the participants who consented to this research also 
consented to the clinical trial. and consequently the original research hypotheses were 
rendered unanswerable. Advice from a statistician and the research supervisor were 
sought. A large number of approaches were possible and an exploratory one was 
selected. It was decided to examine the group of participants in terms of their attitudes 
to medical research and clinical trials to see if they were a unitary whole or whether 
differences existed between them. 
The hierarchical cluster analysis of the attitudes questionnaire identified two main 
groups of participants. Cluster 1 showed a mixture of positive and negative responses 
to the attitudes questionnaire. Cluster 2 showed highly positive attitudes. The cluster 
analysis also identified one participant whose responses were different from the other 
two groups. Examination of this participant's scores revealed mainly negative views 
towards medical research. Interestingly, this patient still entered a trial. 
The two main clusters significantly differed on their responses to the hypothetical trials. 
The more positive group indicated that they were more willing to enter the trials. No 
significant differences were found on any of the psychological scales, number of years 
education, or on the disease related information. It can be concluded that patients' prior 
beliefs and views predict how they believe they would respond given the choice of 
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entering a clinical trial. This gives some support to the view that a pre-held bias 
determines whether or not a patient will enter a clinical trial (Bujoria~ 1988). 
However, it is acknowledged that hypothetical trials have questionable validity and 
their use has been criticised here and by other authors. It was an original aim of this 
research to investigate the validity of these measures. Unfortunately, it is not possible 
to draw conclusions due to the absence of data from patients who refused to enter a 
trial. It is interesting that the patient identified by the cluster analysis, who had negative 
views and expressed the lowest willingness to enter the hypothetical trials, still entered 
the trial proposed to her. This queries the validity of the measures. In additio~ the 
qualitative analysis showed that patients thought the hypothetical trials were different 
from the real decision. 
The difference between the two clusters on the EPQ-Neuroticism scale approached 
significance. This suggested that cluster 2, who expressed highly positive attitudes, 
were a group that were more prone to worry, depression and 'emotionality'. 
It was noted that cluster 2 (highly positive attitudes) had a mean time since first 
diagnosis of 22 months. This was lower than cluster 1 (mixed attitudes), who had a 
mean of 45 months. This difference was not statistically significant, but does suggest a 
trend of a longer duration of disease being related to less positive attitudes. This is not 
statistically supported, or indeed necessarily a causative relationship. 
Further exploratory analysis of the data aimed to explore patients' perception of choice 
(as investigated by question 12 on the attitudes questionnaire) and how this related to 
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other variables. Choice was identified in the literature review as an important concept 
for patients. 
Participants were divided into three groups according to their response to question 12 
(see appendix VI). The analysis showed that participants' perception of their amount of 
choice when faced with the decision was related to scores on the Eysenck Personality 
Questionnaire - Neuroticism Scale. The group who viewed themselves as having the 
highest degree of choice had the lowest EPQ-N scores. The Neurotisicim or 
emotionality scale considers an individual's proneness to worry and depression. The 
higher the score the more likely the person is to be a worrier, suffer from depression, 
sleep badly and have a preoccupation with things that may go wrong. Hence, in this 
study cancer patients with higher degrees of these characteristics perceived themselves 
as having no other choice when asked by their doctor to enter a trial. 
Differences were also found between the three groups on the EPQ-Psychoticism scale. 
Psychosis is considered to be the 'pathological exaggeration of high degrees of some 
underlying trait of Psychoticism' (Eysenck and Eysenck, 1991). The scale is also 
termed 'tough-mindedness'. A high scorer on this scale would be a solitary person, 
who lacks empathy and care for others, has a disregard of danger and is cruel. The 
EPQ-P mean scores of each group were not more than one standard deviation above the 
mean of the standardisation group, and so were not abnormally high. The analysis 
showed that the group with the lowest scores on this 'tough-mindedness' scale saw 
themselves as having the highest degree of choice if asked by their doctor to participate 
in a trial. 
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The P and N scales were significantly positively correlated in this sample. It may be 
the case that patients who feel the most compelled to do as their doctor has asked and 
cannot see alternative choices, are those who have higher degrees of anxiety and 
emotionality and less empathy, care for others and sensitivity. 
However, other variables may account for the reported differences. In the normative 
data presented in the manual (Eysenck and Eysenck, 1991) the EPQ-P scores for the 51-
60 year age group are lower than for the 61-70 age group. Choice group number 3 had 
a mean younger age than the other two groups and fell into the former age band, while 
groups 1 and 2 fell into the latter. We would therefore expect group 3 to have lower 
scores. In addition, group three contained a higher percentage of females, who again 
have lower EPQ-P scores according to the normative data. Hence, it may be that 
younger females perceive themselves as having the higher degrees of choice than older 
males. 
This does not apply to the EPQ-N scale fmdings, as females (and hence group 3) would 
be expected to have higher N-scores according to the normative data. In addition, N 
scores are affected by age in the opposite direction than the one observed in relation to 
'choice'. This fmding is thus more robust than the EPQ-P fmdings. 
On the Multi Dimensional Health Locus of Control scale statistically significant 
differences were found between the three groups. The relationship was observed that as 
perception of choice increased, scores on the Internal scale decreased. The Internal 
scale measures the degree to which a person sees herselfas in control of her own health. 
It was found that a person who saw her health as controlled by internal factors was 
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likely to see herself as having little choice when asked by her doctor to enter a trial. 
This fmding is perhaps unexpected. It is in contrast to previous fmdings that patients 
with a high internal locus of control showed less reliance on their doctor's advice and 
were less likely to enter a trial (Verheggen et aI., 1998). The two studies are, of course, 
not directly comparable as they use different scale and concepts. 
Statistically significant differences between the choice groups were also found on the 
Powerful Others scales of the MDHLC. The trend was observed that as perception of 
choice increased, the scores on the Powerful Others scale decreased. This scale is a 
measure of a person's belief in others' (particularly doctors') control over their health. 
The fmding that patients, who have a high belief in others' control over their health, 
regard themselves as having no other option when asked by their doctor to enter a 
clinical trial is perhaps expected. It can be concluded that the doctor may easily 
influence these patients, and this has implications for informed consent, where it is 
essential the patient is making an informed choice of their own. 
It is again possible that other uncontrolled variables are responsible for the observed 
differences. Data are not provided for this scale according to age or sex. It is noted that 
group 3 had a particularly low Internal score when compared with the data provided by 
Watson et aI. (1978). This may be a distorted view produced by a small sample size. 
This research considered the views of an important relative of the patient. Previous 
research has suggested that cancer patients consult with their relatives before making a 
decision regarding treatment (Tabak, 1995). Research has also shown that family 
members may put excessive pressure on the patient to accept experimental treatment 
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(Peri, 1981). It may be hypothesised that relatives' scores on the hypothetical trials 
would reflect greater willingness to enter, than the scores of the patients themselves. 
The relatives' attitudes to trials may be predicted to be highly positive, reflecting a 
desire for the patient to enter 'no matter what'. However, the results did not support 
this. The patient and relative groups showed very similar mean scores on the 
hypothetical trials and attitudes questionnaire total score, suggesting no difference in 
their overall views. 
The majority of patients (96.7%) indicated that they would take their family's views 
into account, but the correlation between each patient's and their relative's scores was 
not significant. This showed that within a couple or family there may be different 
views. Examination of the data showed that the score differences were in both 
directions; in some cases the relative was more positive and vice versa. It emerged 
from the qualitative data that while the patients talked to their relatives, with the wish to 
ensure that the relative felt comfortable with the trial, they also felt concurrently that no 
one could have changed their mind. It appears that for patients the decision is more of a 
personal one than previously suggested. 
It was a foreseen problem that couples would consult each other when completing the 
questionnaires. The fact that their views were not correlated suggests they did not, and 
this increases the validity ofthe scores. 
Qualitative methodology has been proposed as an appropriate and desirable 
methodology for investigating patients' perspectives of cancer clinical trials (Cox, 
1998). The qualitative results of this research revealed important insights into the 
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experience of being diagnosed, deciding to enter a trial and of trial treatment. These 
contribute to the existing literature. The four patients interviewed discussed very 
similar issues and consistent themes emerged from them in the analysis. The most 
salient findings will be now be discussed. 
An important and new fmding was that entering the trial was not a difficult decision for 
the patients and that they did not consider refusing. The patients were not fully aware 
of the alternatives, or in some cases, even if there was one. This may at least in part 
explain the 95.9% consent rate found in this study. The decision to enter a trial has 
been conceptualised by previous research and assumed at the start of this study to be 
difficult for patients. It appears that this is not the case. The trial was a treatment for 
these patients, it did not matter whether it was experimental or standard, and they did 
not consider refusing. They did not think about its experimental nature in any depth. 
Patients who refuse a trial may consider the experimental nature important, but it was 
not possible to interview these patients. The qualitative results are based on a highly 
selective group of patients and important insights would have been gained from patients 
who refused trial entry. 
Patients did not distinguish between different types of research. They considered new 
treatments, blood tests for research and x-rays being shown to medical students, as 
much the same thing. This suggests that the patients did not fully understand the nature 
of the clinical tria~ despite information sheets from both this research and the trial. 
Given their lack of knowledge of alternatives, it would seem that the view that patients 
make their decisions on incomplete and inaccurate information (Sutherland et al., 1990) 
is supported. 
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The results supported previous fmdings that the desire to help others and to survive 
were the important motivations for entering the trial (Cox and Avis, 1996; Stetz, 1993). 
Similar themes of 'nothing to lose' and 'having to try something' emerged. It was 
noted by the researcher during the interviews that the patients described the desire to 
help others less frequently than helping themselves. For these patients the primary 
motivation for entering the trial was not an altruistic one. Comments patients make 
about helping others may at times be socially desirable responses. 
Cox and Avis (1996) noted that patients perceive they have no choice when offered a 
trial. The fmdings of this research question this view. All four patients knew explicitly 
that it was their choice to enter, that they could say yes or no, and that participation was 
voluntary. However, this did not equate to the patients having to make a decision 
between two or more alternatives. They knew they had a choice in theory, but this was 
not a 'real choice' for them. There appears to be a difference between 'knowing' and 
'feeling' that they actually had a choice. 
The fmdings showed that patients made their decision during a time of emotional shock 
and feelings of horror. This is consistent with previous research (e.g. Thorton, 1992). 
However, the trial proposal was not seen as unwanted by patients; it was in fact 
received with relief that something was being offered. 
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4.2 Discussion of Methodological Issues 
Recruitment 
This research suffered profound, unforeseen recruitment problems. Despite early 
predictions of fulfilling the number of participants needed to meet the power calculation 
(N= >120), when data collection began it became apparent there were fewer eligible 
patients than predicted. There were less clinical trials being conducted, which required 
fewer participants, than the researcher had originally been told to expect. A second 
consultant oncologist within the department was approached for permission to include 
his patients in the study. The oncologist consented, but was unable to offer assistance 
in the identification ofthe patients for the study. 
Two further centres were approached in geographically distant regions. One declined 
due to existing research demands on patients. The other agreed, but despite 
considerable efforts by the researcher, the application for ethical approval in that region 
could not be submitted within the time constraints of the study. 
The process of recruitment also suffered considerable difficulties. Initially, the 
questionnaires were planned to form part of an interview held in the clinic when the 
patient came to see the consultant, before they were offered a trial. Preliminary 
discussions with experienced oncologists, nurses and with a small number of patients 
indicated this as a suitable environment and time point. However, during the early 
stages of data collection an interview had to be discontinued due to patient distress. It 
was felt that this was not the time to be placing unnecessary pressure on patients and 
perhaps placing them in a situation where they felt they could not refuse participation. 
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It was also apparent that a patient's only focus was on what the doctor was going to tell 
them and that they were too anxious to accurately complete the questionnaires. Hence, 
due to ethical considerations, the design was reconsidered with the research supervisor 
and consultant oncologist. It was decided to change the design to a cross-sectional, 
postal questionnaire (see Chapter II: Methodology), so that patients could participate in 
their homes when feeling less anxious. Patients who did not want to participate would 
not feel pressurised to consent. It was acknowledged that this would probably lead to a 
lower response rate. 
These changes were proposed to the Local Research Ethics Committee and ethical 
consent was granted one month later. This shortened the planned data collection 
period. 
Once data collection began further difficulties in recruitment were experienced. The 
researcher was relying on a busy clinical trials nurse to identify and dispatch the 
prepared questionnaire packs. The trials nurse was in tum dependent on the 
consultants' secretary to give her the referrals for screening before they were sent ofT 
for appointments to be arranged. This proved to be impossible as the administration 
staff frequently forgot. The procedure was changed so that the trials nurse met 
regularly with the two c'onsultants to identify eligible patients. This was found to be the 
best method, but was unfortunately different from the original proposal where the 
oncologists themselves would identify patients as soon as referrals were received, and 
then alert the trials nurse to send out the questionnaire pack. The recruitment process 
employed was unsatisfactory d,ue to its reliance on the nurse's memory and time. It is 
possible that it led to many appropriate referrals slipping though unnoticed. 
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It is apparent that the 95.9% consent rate to clinical trials is a highly unreliable figure. 
It is unknown how many patients were asked to enter a clinical trial, but did not receive 
a questionnaire pack. 
There was also no way of ensuring that patients completed the questionnaires before 
they were approached about the trial. They would have received the questionnaires 
before being approached, but it was not checked when the pack was returned, due to 
practical and communication difficulties. Patients' responses may have been 
contaminated by their decision to enter the trial. 
The telephone calls to patients who had not responded 10 days after the questionnaire 
pack had been dispatched had to be discontinued. This was due to unavailability of the 
trials nurse for consultation regarding the patients' medical status at appropriate times. 
Data concerning patients' reasons for not responding were therefore not available. This 
is unfortunate, as insights may have been gained from these patients. 
The literature review found shortcomings in previous research. Studies were criticised 
on the grounds that their samples included patients with new and recurrent disease, in 
phase I, IT, and III trials and with different types of cancer. This research failed to 
rectify these shortcomings. It was initially planned to use only phase III clinical trials, 
but this had to be extended to include phase I and II given the lack of eligible patients. 
Again, it was planned to recruit only patients with newly diagnosed disease, but the 
sample was extended to those with recurrent disease to increase numbers. However, the 
majority of patients were newly diagnosed with the cancer for which they were offered 
the trial. It was not possible to focus on one type of cancer, again due to problems in 
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recruiting eligible patients. This research did exclude surgical clinical trials and all the 
patients recruited were offered a chemotherapy clinical trial. However, post hoc 
analysis of the trials revealed that one was a trial of a vaccine for patients who were 
currently disease free (see Appendix I). It can be concluded that the sample in this 
research was a highly heterogeneous group in terms of disease and treatment related 
variables. 
Differences between responders and non-responders may exist. This is a problem 
inherent to all research where participation is voluntary. It is a particular difficulty 
associated with postal questionnaires, which often have low response rates. However, a 
reasonably high response rate of 63% was obtained in this study, which increased the 
representativeness of the views expressed. It may be that patients with positive views 
about research were more likely to enter this project and report positive views about 
clinical trials. This study is likely to have obtained a skewed picture of trial 
participants' opinions. 
On the variables of age and sex there were no statistically significant differences 
between the responders and non-responders. This suggests that the responder group 
was representative of the population on some variables. 
The sample had a mean age of 59.5 years (SD 10.1) and contained approximately equal 
numbers of males and female participants. The majority was married and had 
completed education to the secondary level, although considerable numbers had further 
education. Approximately half (45%) of the sample, were in, or retired from, an 
unskilled occupation. It is difficult to say if this sample is representative 0 f the clinical 
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trial population or if it is related to local socio-economic factors. The fmdings may be 
limited in their generalizability to the rest of the population. It would have been 
advantageous to use a number of centres in different geographical areas to overcome 
this difficulty. 
The design selected was a cross-sectional postal questionnaire. As already discussed, 
postal questionnaires suffer from low response rates leading to problems in generalizing 
from the results. In addition, it was found that some participants incorrectly or 
incompletely filled in the questionnaires, leading to missing data. There was no way of 
checking that they understood the questions, so respondents may have interpreted them 
in different ways. Participants may also have asked the views of others before 
answering. It is questionable whether we measured the participants' views or those of 
their friends and family. 
The cross-sectional design was appropriate to the research hypotheses. The researcher 
was interested in patients' attitudes, emotional status, coping and personality at a 
particular point in time and how these factors affected their decision regarding a clinical 
trial. This would not have allowed causal relationships to be established, but would 
have allowed comparison of those who consented with those who refused a clinical 
trial. This design was also appropriate to the time limits ofthe data collection period. 
Statistical Analyses 
This research suffered from the problems of a small sample size and the existence of 
only one group of participants, rather than two as planned. The data obtained could not 
be used to answer the research hypotheses. It was necessary to adopt an exploratory 
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approach and to look at the characteristics of the group of patients who consented to a 
cancer clinical trial. 
It is acknowledged that the reported results are only a small proportion of the potential 
number of analyses of the relationships between the variables. It was considered 
important to select questions that related to the early aims ofthe study and the fmdings 
of the literature review; for example, to look at the concept of choice, the influence of 
relatives and health locus of control. It is acknowledged that by completing a series of 
Independent T-tests, Mann Whitney U Tests and correlations that statistically 
significant results would be found according to chance. The likelihood of making Type 
I errors was increased and to avoid this the Baroffsky Correction was suggested. None 
of the significant results remained so once this correction was applied. In fact, many of 
the results observed were only significant at the 95% confidence level. Consequently, 
the results of the statistical analyses cannot be considered robust and need to be 
interpreted with caution. 
The use of non-parametric statistical analyses, which are less powerful and so less 
likely to detect an effect of the independent variable on the dependent variable, 
increased the likelihood of a type II error. Some relationships may have overlooked. 
Qualitative methodology and analysis were also used in this research. The aim was to 
combine the two research positions to give a more complete picture of patients' 
experiences. A semi-structured interview was used, with pre-determined, open-ended 
questions. During these interviews every care was taken to follow up the issues brought 
up by the participants and to obtain a picture of their reality, whist providing some 
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structure to the interview. It was not a necessity to adhere rigidly to the interview 
questions. 
Qualitative research is often criticised as sUbjective and influenced by the researcher's 
own biases. In this research it is acknowledged that the prior views of the researcher 
did intrude on the interviews in terms of the questions selected. However, it was made 
clear in the results chapter that the initial three categories into which the responses were 
placed were predefmed, and did not emerge from the data It is felt that the sub-
categories that emerged within these were dependent on the participants' responses and 
were not merely a reflection of the researcher's interests. The use of another individual 
to categorise the data who was not familiar with the relevant literature increased the 
validity and reliability of the fmdings. The second rater approached the data differently 
and identified themes that ran through the researcher's sub-categories. 
Content analysis was selected as it potentially allowed the emergence of similarities and 
differences between patients' experiences. By creating categories, important themes 
were observed that were common to the patients and were useful in explaining other 
fmdings of the research. However, it is acknowledged that by breaking up the data in 
this way the complete experience of each individual may have been lost. 
The qualitative fmdings of this research are based on only four patients, all of whom 
consented to a clinical trial. They cannot be considered representative of the whole 
population and so the results cannot be generalized. Previous qualitative projects have 
also focused on patients who have consented to trials and not those who have refused 
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(e.g. Cox, 1999). This deficiency in the literature was identified in the review and it is 
unfortunate that this project could not rectify this. 
Measures 
The attitudes questionnaire was designed by the researcher for this study. Without a 
comparison sample, it is difficult to say whether this measured underlying beliefs that 
are related to trial consent or refusal. Also without a 'normative' sample, it is not 
possible to consider whether this group were highly positive or whether their attitudes 
were same as those of the general population. However, patients showed a variety of 
responses and by hierarchical cluster analysis it was possible to identify two groups of 
patients according to this questionnaire. 
The hierarchical cluster analysis also showed that the majority of the questions were 
measuring the same construct. It is felt that the questionnaire did measure prior views 
of research and trials in general, although further research using this measure would be 
needed to confirm this. The use of the 'total score' in the analysis as an overall 
measure of attitudes may have led to the neglect of important differences on the 
individual questions. 
The hypothetical trial scenarios were designed for this study by a consultant oncologist 
and the researcher. As detailed in the methodology section, they were designed to 
measure a patient's willingness to enter different types of trials. For each trial, different 
factors were important, such as side effects, predicted effectiveness and the absence of 
another treatment option. However, it is questionable whether patients understood the 
differences between the scenarios. The scores on all four scenarios were highly 
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correlated with each other (see Appendix XVII) and so it was decided to use the 'total 
score' in the analyses, as a measure of willingness to enter trials. The normal 
distribution of this variable also allowed the use of parametric statistics, which 
increased the power of the analysis. However, by using this total score it is possible 
that differences between the scenarios were overlooked. 
The hypothetical trial total score and the attitudes questions total score were 
significantly correlated, which supports the view that they were measuring some 
underlying trait or view point. It cannot be concluded how these relate to behaviour. 
4.3 Summary and Conclusions 
This research set out to explore the differences between cancer patients who consented 
to a clinical trial and those who refused. However, this comparison was not possible. 
Recruiting difficulties were experienced and the final sample consisted only of patients 
who had consented to a cancer clinical trial. As in previous research, this meant that 
patients who refused to enter were not included. This group remained an elusive 
proportion of patients. The high consent rate demonstrated in this study casts doubt on 
patient refusal as a significant problem in cancer clinical trial research. 
Two groups of patients could be identified according to their attitudes towards research 
and these groups differed on their Willingness to enter hypothetical trials. It appears 
that these two questionnaires were measuring patients' underlying views. However, it 
is not possible to say whether patients who refused a clinical trial would report less 
positive views. 
124 
A patient's rating of their amount of choice if asked to enter a trial was related to their 
personality and health locus of control. Although the concept of choice is complex and 
this research addressed a very limited part of this, the fmdings have important 
implications for the process of informed consent. 
The qualitative fmdings of this project showed that patients did not know of the 
alternatives to the trial. The research also showed that patients who are more prone to 
worry and depression are likely to be unable to see that they have alternative choices. 
In the situation of being offered a clinical trial they are easily influenced by their 
Doctor. The results also showed that patients who place the responsibility of their 
health in professionals also perceive themselves as having no choice if offered a clinical 
trial. These patients are easily influenced by the doctor. 
The fmdings also suggested that patients with a high internal locus of control perceived 
themselves as having no choice if offered a trial by their doctor. As discussed earlier 
this fmding was inconsistent with previous research. This fmding highlights the 
complexity of the issue of choice. It may be the case that by choosing to enter a trial 
patients feels they are actively making a choice and that they are actively doing 
something to fight their disease. Even ifthey were not aware of alternatives, the patient 
considers that they are still making a choice. This is consistent with the qualitative 
fmdings which showed that patients knew they had a choice, felt they had made one, 
but concurrently did not know of the alternatives. In this situation making a 'choice' 
did not mean deciding between two or more alternatives. 
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Informed consent requires that the patient is making a fully informed choice. This 
research suggests that the informed consent process needs to be tailored to individual 
needs and the personality and beliefs of the patients taken into account. The doctors 
and research staff need to be aware that their opinion is highly influential on some 
patients'decisions. These patients need help to weigh up their choices. More emphasis 
on the actual alternative treatments needs to be made and it be confIrmed that the 
patient is aware of them, even if the alternative is no treatment. Patients need more 
time to consider the implications ofthe trial and the alternatives. 
Finally, the qualitative fmdings of this study added insights into patients' experiences 
and concepts of clinical trials and their decision to enter. 
It is clear that the experience of a clinical trial is highly SUbjective and has many 
different meanings for patients. A patient's decision appears to be dependent on a large 
number of factors, which include the characteristics of the trial itself, the doctor's 
attitudes and opinion, and the patient's medical status. The psychological 
characteristics and attitudes of the patient are likely to form just one part of an 
interaction between many influences. 
It is concluded that future research needs to speciflcally address the issue of how to 
include patients who refuse a clinical trial. It is important to explore the characteristics 
and viewpoints of these patients, using both qualitative and quantitative methodologies. 
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APPENDIX I 
INCLUSION CRITERIA FOR CLINICAL TRIALS 
AIM HIGH - A phase II study of observation vs low dose extended duration interferon alpha- 2a in high 
risk resected malignant melanoma. 
• Patients with histologically proven malignant melanoma and high risk of recurrent metastatic disease 
with either: 
histologically proven metastatic melanoma in regional lymph nodes after therapeutic radical regional 
node dissection at initial presentation, 
or 
histologically proven metastatic melanoma in regional lymph nodes after therapeutic radical regional 
node dissection at subsequent recurrence, 
or 
Non-nodal superficial regional recurrence (local or in-transit disease), 
or 
Primary tumours 4 mm or more Breslow thickness without any detectable focus of metastasis. 
• Fit to receive interferon if allocated. 
• Less than 12 weeks since resection. 
• Healed surgical wound 
• Clinically disease free. 
• No history of malignant disease. 
• Not pregnant or lactating. 
• No previous biological therapy. 
• Not on steroids or immunosuppressive therapy. 
• Written informed consent. 
ill-A phase II trial of BBR3464 in patients with gastric or gastric-oesophageal adenocarcinoma who 
havefailedfirst line chemotherapy. 
• Patients with histologically ~r cytologically proven inoperable, locally advanced or metastatic gastric or 
gastro-oesophageal adenocarcmoma who have failed frrst line treatment 
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• Aged at least 18 years. 
• Life expectancy of at least 3 months. 
• WHO performance status of 0-1 . 
• Patients must have measurable disease as measured by x-ray or CT scan . 
• Carbon Monoxide Diffusion capacity must be at least 50% of predicted value. 
• Recovery from acute toxicities. 
• Written consent from the patient prior to the study. 
• Patient must be able to co-operate with the treatment and comply with the requirements of the study 
protocol for the duration of the trial. 
• Patients with brain metastases are eligible provided they have stable symptoms and a stable dose of 
steroid within one month of receiving the study drug and are able to give informed consent. 
FOCUS - A randomised phase II trial to assess the role of irinolecan and oxa!iplatin in advanced 
colorectal cancer 
• Histologically confirmed adenocarcinoma of the colon or rectum. 
• Inoperable metastatic or locoregional disease (synchronous or recurrence). 
• No previous chemotherapy for established metastatic disease . 
• Measurable or evaluable disease. 
• Adequate bone marrow, renal and hepatobiliary function . 
• WHO performance status 0, 1 or 2 and are considered fit to undergo all possible treatments. 
• Not pregnant and are using adequate contraception. 
GEMCIT ABINE- A phase UII study of chemo-radiotherapy USing gemcitabine (2FdC) as a 
radiosensitiser for brain metastasesfrom adencarcinomas. 
• Histological/cytological diagnosis of adencarcinoma predating, antedating or synchronus to the brain 
metastases for which gemcitabine is an accepted therapeutic agent 
• Performance status equal to or less than 2. 
• Able to co-operate with intended RT treatment. 
• Ability to understand the trial requirements and give informed consent. 
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• No concurrent or metachronous or antedating malignancy of other organs except of basal cel1 carcinoma 
of the skin and in-situ carcinoma of the cervix, both adequately treated. 
• Adequate haematological, renal and liver functions for chemotherapy. 
• No age limit 
• No surgical procedures to the brain 
• Stable on steroids 
• Metastases measuring 2x2x2cm or more on staging cr scan. 
• Signed consent form. 
ISIS - A phase III prospective, randomised. open-label trial of chemotherapy with carboplatin and 
- paclilaxel, vs carhoplalin and paclitaxel in combination with isis 3521, in antisense previously 
untreated, non-small cell lung cancer. 
• Patient is:::: 18 years old . 
• Patient is using an effective form of contraceptive. 
• Patient has histologically or cytologically confirmed diagnosis of non-small cell hmg cancer. 
• Patient has Stage IV disease or Stage IIIB with malignant pleural or pericardial effusion. 
• Patient has either: 
At least one unidimensional measureable lesion, 
or 
Non-measureable, evaluable disease . 
• Patient has signed consent form. 
• ECOG is $1. Patient is able to perform light houseworklofficework (if not ECOG =2). 
• Serum creatine is $ 1.5mgldL; Serum bilirubin $ 1.5mgldL. 
• Serum asparate aminotransferase concentration < 3 x ULN. 
• ANC is:::: 1500/mm3; platelet count:::: 100,OOO/mm3; haemoglobin is ~ 10.0 g/dL. 
MT A OOX - A phase 1, dose-escalating study of MTA and Doxorubicin administered every 21 days in 
patients with locally advanced or metastatic cancer. 
• Histologic or cytologic diagnosis of locally advanced or metastatic cancer. 
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• Previous chemotherapy is permitted . 
• No other chemotherapy for 4 weeks before enrolment in the study. 
• Performance status 0 to 2 on the WHO scale . 
• Evidence of locally advanced or metastatic disease. Can be measurable, evaluable or non-measurable. 
• Life expectancy of at least 12 weeks. 
• Prior radiotherapy allowed to 25% of bone marrow producing areas. 
• Patient compliance and geographic proximity that allow adequate follow-up. 
• Adequate organ functioning. 
RFA - A phase II study of combination primary chemotherapy (Campto-5FUIFA) followed by RFA 
- (radiofrequency ablation) for patients with low volume inoperable liver metastases from colon 
cancer. 
• Patient with metastatic colorectal cancer isolated to the liver who is classified as inoperable due to 
anatomical or performance status considerations . 
• Histological diagnosis of colorectal cancer. 
• Accessibility of lesions to an RF A probe. 
• Patients have received prior chemotherapy, which has been discontinued for 4 weeks prior. 
• Histology of liver metastases for metachronous lesions. 2 years post surgery. 
• Number oflesions ==: 6. With any single lesion maximum diameter ==: 3.5cm . 
• Performance status (WHO) score I or O. 
• Life expectancy longer than 3 months. 
• Liver function (Bilirubin < 1.5 x ULN transminases < 5 x ULN) 
• Renal function (serum creatinine ==: 135 wnol) 
• Haematological function (ANC:52 x 109/L and platelets :5150 x l09IL) 
• Normal coagulation profile. 
• Lesions demonstrated by ultrasound or Fluroscopy. 
THERA TOPE® - A multi-centre phase III. randomised, controlled study of Theratope vaccine for 
metastatic breast cancer. 
• Previously diagnosed (histologically or cytologically confirmed) breast cancer. 
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• Has received between 4-8 cycles of first line chemotherapy for metastatic disease. 
• Has either (a) no evidence of disease or (b) non-progressive disease following flfst line chemotherapy. 
• Has aneurophil count~ 1.0 x 1091L; platelet count~ 75 x 1091L; haemoglobin ~ 9 gldL. 
• Has performance status of ~ 2 on the ECOG scale. 
• Is female and at least 18 years old 
• Is considered reliable and has signed the consent form. 
• Is accessible for treatment and follow-up. 
TULARIK - A phase II, two arm, open label study of T138067-sodium in breast cancer patients who 
have failed up to two prior regimes for locally advanced breast cancer. 
• Pathologic diagnosis of breast cancer. Locally advanced or metastatic disease. 
• Any amount of prior adjuvant chemotherapy. 
• Any chemotherapy or major surgery must be completed at least 4 weeks before study treatment 
• Patients must have recovered from the acute side effects of radiotherapy. 
• Patients must hve bi-dimensionally measurable disease amenable to radiologic imaging techniques . 
• Female, at least 18 years of age. 
• Kamofsky performance status of 70 or greater . 
• Estimated life expectancy of at least 12 weeks. 
• Must be using effective contraception. 
• Able to comply with study procedures and follow up procedures. 
• Patient signed consent form. 
• Patients must have adequate organ function. 
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PATIENTS' INFORMATION SHEET 
PEOPLES' VIEWS ON CANCER CLINICAL TRIALS 
You are being invited to take part in a research study. The following information tells you why the 
research is being done and what it will involve. Please take time to decide whether or not you wish to 
take part. 
What is the purpose ofthis study? 
We are interested in what people think about clinical trials. We would like to work out what makes some 
people want to enter a trial and what makes others not want to. 
This study is NOT asking you to enter a clinical trial, we are just interested in your opinions. 
What is a Clinical Trial? 
A clinical trial is a study that tries to test whether a new treatment is better than an existing treatment 
Although treatments for cancer have improved; we still do not know all the answers. Clinical trials are 
the means by which we find those answers. Involvement by patients in clinical trials is purely voluntary. 
In a trial a patient is randomised (selected by chance) to have either the standard treatment (which may 
be nothing) or the new treatment 
Why have I been chosen? 
You have been chosen because your cancer is newly diagnosed. Up to 200 other patients will also be 
studied over the next year. We are also asking your relative/friend to help with the study. 
Do I have to take part? 
It is up to you whether or not you take part. If you do take part you must sign the consent form included 
in this pack. You can withdraw from the study at any point. 
Your decision will not effect the standard of care you receive. 
The study is separate to your medical care and your consultant wilt not be contacted about your individual 
results. 
What should I do now? 
1. Some of the questionnaires in this pack are for you and there are also a small nwnbcr for me of 
your relatives or friends to fill in. 
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2. The ones for your relative/friend are on blue paper and are marked "relative/friend" in the top 
left comer. Please choose someone whom you are close to (possibly the person who attends 
your hospital appointments with you). Your relative/friend will have an information sheet like 
this one telling them what to do. 
3. After reading this information sheet please sign the consent form. 
4. Then fill in the questionnaires included in this pack. There are 7 all together. This will take 
about 35 minutes in total, but you don't have to do them all at once. It is impa1ant that you do 
this before your first clinic appointment 
Only put your name on the sheet entitled ''personal Information". DO NOT put your name on 
any other of the questionnaires. 
Please read the instructions on the top of each of the questionnaires carefully and answer all 
questions. Please note, the pink questionnaire has questions on the back too 1 
Please do not confer with your relative while filling them in. You are welcome to share answers 
afterwards! 
5. You should put your and your relative's completed questionnaires in the envelope and bring it to 
your first clinic. Alternately, return them in the pre-paid envelope. 
6. We will contact you again in approximately 3 months to ask you to participate in a further 
interview. If you have agreed to participate in the study today you do not have to take part in 
the second interview. 
Will my taking part be kept confidential? 
All information collected about you will be kept strictly confidential. All information that leaves the 
hospital will have your name removed from it 
What will happen to the results of the research study? 
The results of this study are likely to be published after the summer of2001. You will not be identified in 
any report or publication. We will send you a copy of the results if you wish. 
Who has reviewed this study? 
This study has been reviewed and passed by the Hull and East Riding Local Research Ethics Committee. 
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Who should I contact for further information? 
Professor M. Lind. 
Department of Academic Oncology 
Princess Royal Hospital 
Salthouse Road 
Hull 
THANKYOU FOR TAKING PART IN THE STUDY 
You will be given a copy of this information sheet and a signed consent fonn to keep. 
14.09.00, Version 3 
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PATIENT CONSENT FORM 
Patient identification number for the study D 
Title of Project: Psychological Factors that Influence Patient Participation in Cancer 
Clinical Trials. 
Name of researcher: Cheryl Jane Davis, Trainee Clinical Psychologist 
1. I confirm that I have read and understood the infonnation sheet dated 14.09.00 (version 3) for the 
above study. ~
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
3. I understand that sections ormy medical notes may be looked at by the above named researcher. I 
give my permission for this. 
4. I agree to take part in the above named study. 
Name of Patient 
Name of person taking consent 










PATIENT DEMOGRAPHIC INFORMATION 
Participant nwnber D 
PERSONAL INFORMATION 
Name 
Date of birth , , 
Occupation 
(ifhousewife, what is the occupation of your husband?) 
(if retired, what was your job previously?) 
Marital status: 




At what age did you leave school? 
Have you any other medical problems? (Please tick) 
If yes please give brief details: 
Yes No 
Have you had any other major problems/events in the last 6 months? 
(For example, Wlemployment, relationship break-up, financial problems etc.) 
(please tick) 





HYPOTHETICAL TRIALS - PATIENT VERSION 
This booklet contains descriptions of 4 situations sometimes faced by patients. 
These situations have been made up by us, but are based on previous real-life cases. 
Please read each one carefully and imagine that the situation is real. 
Circle the answer which best describes what you think you would do if faced with the decision. 
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1 
Your consultant tells you that the standard treatment for your disease will not help. However, there is a 
new drug, which may help. 
The consultant tells you about a clinical trial in which you would either receive: 
no treatment 
or 
the new drug. 
It would be decided by chance which of these you would receive. You would have an equal chance of 
receiving either one. 


















APPENDIX V (CONTINUED) 
2 
Your consultant explains to you that the standard treatment for your disease is drug A. There is also a 
new (experimental) treatment that may be helpful, drug B. 
Drug A has very few side effects. 
Drug B has a lot of side effects. 
There is a clinical trial where it will be decided by chance whether you receive drug A or drug B. 
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3 
Your consultant explains to you that the standard treatment for your disease is drug A. There is also a 
new (experimental) treatment which may be helpful, drug B. 
Drug A has a lot of side effects. 
Drug B has very few side effects. 
There is a clinical trial where it will be decided by chance whether you receive drug A or drug B. 
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4 
Your consultant explains to you that there is no right or wrong treatment for your disease. 
There are 2 treatments that are thought to be similarly helpful. 
They have similar side effects. 
There is a clinical trial where you will receive one of these treatments. Which one you receive will be 
decided by chance. 



















ATTITUDES TO TRIALS AND RESEARCH QUESTIONNAIRE-
PATIENT VERSION 
Please read each of the following questions and put a circle around your answer. If none of the 
options describes how you feel, just choose the closest one. Please answer all questions. 
We are interested in your opinions. There are no right or wrong answers. 









2) To develop new treatments for cancer, I think clinical trials are: 
1 2 3 4 
very somewhat neither somewhat 
necessary necessary needed wmecessary 
or 
not needed 
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4) How much do you agree with this statement? 










5) How much do you agree with this statement? 
4 
disagree 


















6) How would participating in a trial. rather than receiving the standard treatment effect your ho~ 






















How do you think participating in a clinical trial would effect a patient's chance of survival 
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8) How much do you agree with this statement? 
















This means the patients who volunteer could receive anyone of the treatments in the trial. They 
cannot choose which one. 



















This means that neither the doctors or yourself would know which treatment you were receiving. 


















un com fortable 
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11) How much do you agree with this statement? 
















12) If you were asked to participate in a clinical trial how much would you take the views of your 






13) How much do you agree with this statement? 
4 
not at all 



















HOSPITAL ANXIETY AND DEPRESSION SCALE 
Doctors are aware that emotions play an important part in most illnesses. If your doctor knows how you 
feel he will be able to help you more. 
This questionnaire is designed to help your doctor to know how you feel. Read each item and place a 
firm tick in the box opposite the reply which comes closest to how you have been feeling in the past 
week. 
Don't take too long over your replies: your immediate reaction to each item will probably be more 
accurate than a long thought out response. 
I feel tense or wound up: 
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all 
I still enjoy the things I used to enjoy: 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
I get a sort of frightened feeling 
as if something awful is about to happen: 
Very definitely and quite often 
Yes, but not too badly 
A little, but it doesn't worry me 
Not at all 
I can laugh and see the funny side of things: 
As much as I always could 
A lot of the time 
Definitely not so much now 
Not at all 
Worrying thoughts go through my mind: 
A great deal of the time 
A lot of the time 
From time to time, but not too often 
Only occasionally 
I feel cheerful: 
Not at all 
Not often 
Sometimes 
Most of the time 




Not at all 
I feel as if I am slowed down: 
Nearly all the time 
Very often 
Sometimes 
Not at all 
I get a sort of frightened feeling like 
'butterflies' in the stomach: 




I have lost interest in my appearance: 
Definitely 
I don't take as much care as I should 
I may not take quite as much care 
I take just as much care as ever 
I feel restless as if I have to be on tbe move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
I look forward with enjoyment to things: 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 








EYSENCK PERSONALITY QUESTIONNAIRE- REVISED, SHORT SCALE 
INSTRUCTIONS: Please answer each question by putting a circle around the 'YES' or 'NO' following 
the question. There are no right or wrong answers, and no trick questions. Work quickly and do not think 
too long about the exact meaning of the questions. 












































Does your mood often go up and down? 
Do you take much notice of what people think? 
Are you a talkative person? 
If you say you will do something, do you always keep your promise no matter 
how inconvenient it might be? 
Do you ever feel 'just miserable' for no reason? 
Would being in debt worry you? 
Are you rather lively? 
Were you ever greedy by helping yourselftb more than your fair share of 
anything? 
Are you an irritable person? 
Would you take drugs which may have strange or dangerous effects? 
Do you enjoy meeting new people? 
Have you ever blamed someone for doing something you knew was really 
your fault? 
Are your feelings easily hurt? 
Do you prefer to go your own way rather than act by the rules? 
Can you usually let yourself go and enjoy yourself at a lively party? 
Are all your habits good and desirable ones? 
Do you often feel 'fed up'? 
Do good manners and cleanliness matter much to you? 
Do you usually take the initiative in making new friends? 
Have you ever taken anything (even a pin or a button) that belonged to 
someone else? 
Would you call yourself a nervous person? 
Do you think marriage is old-fashioned and should be done away with? 
Can you easily get some life into a rather dull party? 
Have you ever broken or lost something belonging to someone else? 
Are you a worrier? 
Do you enjoy cooperating with others? 
Do you tend to keep in the background on social occasions? 
Does it worry you if you know there are mistakes in your work? 
Have you ever said anything bad or nasty about anyone? 
Would you call yourself tense or highly strung? 
Do you think people spend too much time safeguarding their future with 
savings and insurance? 
Do you like mixing with people? 
As a child were you ever cheeky to your parents? 
Do you worry too long after an embarrassing experience? 
Do you try not to be rude to people? 
. Do you like plenty of excitement and bustle around you? 
Have you ever cheated at a game? 
Do you suffer from nerves? 
Would you like other people to be afraid of you? 
Have you ever taken advantage of someone? 
Are you mostly quiet when you are with other people? 
Do you often feel lonely? 


















































APPENDIX VIII (CONTINUED) 
Do other people think of you as being very lively? 
Do you always practice what you preach? 
Are you often troubled about feelings of guilt? 
Do you sometimes put off until tomorrow what you ought to do today? 
Can you get a party going? 








MULTIDIMENSIONAL HEALTH LOCUS OF CONTROL SCALE 
This is a questionnaire designed to determine the way in which different people view certain important 
health-related issues. Each item is a brief statement with which you may agree or disagree. Beside each 
statement is a scale which ranges from strongly disagree (1) to strongly agree (6). For each item we 
would like you to circle the number that represents the extent to which you disagree or agree with the 
statement. The more strongly you agree with a statement, then the higher will be the number you circle. 
There more strongly you disagree with a statement. then the lower will be the number you circle. Please 
make sure that you answer every item and that you circle only one number per item. This is a measure of 
your personal beliefs: obviously there are no right or wrong answers. 
Please answer these items carefully, but do not spend much time on anyone item. As much as you can, 
try to respond to each item independently. When making your choice, do not be influenced by your 
previous choices. It is important that you respond according to your actual beliefs and not according to 
how you feel you should believe or how you think we want you to believe. 
Strongly Strongly 
Disagree Agree 
1 If! get sick, it is my own behaviour which determines how 
soon I get well again. 2 3 4 5 6 
2 No matter what I do, if! am going to get sick, I will get sick. I 2 3 4 5 6 
3 Having regular contact with my doctor is the best way for me 
to avoid illness. 1 2 3 4 5 6 
4 Most things that affect my health happen to me by accident. 2 3 4 5 6 
5 Whenever I don't feel well, I should consult a medically 
trained professional. 2 3 4 5 6 
6 I am in control of my health. 2 3 4 5 6 
7 My family has a lot to do with my becoming sick or staying 
healthy. 2 3 4 5 6 
8 When I get sick, I am to blame. 2 3 4 5 6 
9 Luck plays a big part in determining how soon I will recover 
from an illness. 1 2 3 4 5 6 
10 Health professionals control my health. 2 3 4 5 6 
11 My good health is largely a matter of good fortune. 2 3 4 S 6 
12 The main thing that affects my health is what I myself do. I 2 3 4 5 6 
13 If I take care of myself I can avoid illness 2 3 4 S 6 
14 When I recover from an illness, it's usually because other 
people (for example doctors, nurses, family, friends) have 
been taking good care of me. 1 2 3 4 S 6 





APPENDIX IX (CONTINUED) 
If it's meant to be, I will stay healthy. 
If I take the right actions, I can stay healthy. 
Regarding my health, I can only do what my doctor 
tells me to do. 
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1 2 3 4 5 6 
2 3 4 S 6 
1 2 3 4 5 6 
APPENDIX X 
COURTAULD EMOTIONAL CONTROL SCALE 
Listed below are some of the reactions people have to certain feelings or emotions. Read through the 
items on each list and, by circling an appropriate nwnber on the scale indicate how far each describes the 
way you generally react 
For example: In reaction A, if you think you 'almost never' keep quiet when you feel angry or annoyed, 
then you would circle 1. 
Please circle a nwnber for every reaction from A through U. Work quickly and circle one nwnber on each 
line. 
almost sometimes often almost 
WHEN I FEEL ANGRY (VERY ANNOYED): never always 
A I keep quiet 1 2 3 4 
B I refuse to argue or say anything 1 2 3 4 
C I bottle it up 1 2 3 4 
D I say what I feel 1 2 3 4 
E I avoid making a scene. I 2 3 4 
F I smother my feelings I 2 3 4 
G I hide my annoyance 1 2 3 4 
WHEN I FEEL ANXIOUS (WORRIED): 
H I let others see how I feel I 2 3 4 
I I keep quiet 1 2 3 4 
J I refuse to say anything about it 1 2 3 4 
K I tell others about it 1 2 3 4 
L I say what I feel 1 2 3 4 
M I bottle it up 1 2 3 4 
N I smother my feelings 1 2 3 4 
WHEN I FEEL UNHAPPY (MISERABLE): 
0 I refuse to say anything about it 1 2 3 4 
P I hide my unhappiness I 2 3 4 
Q I put on a bold face I 2 3 4 
R I keep quiet I 2 3 4 
S I let others see how I feel I 2 3 4 
T I smother my feelings 1 2 3 4 
U I bottle it up I 2 3 4 
Please check that you have circled one number on each line and that you have circled a nwnber for ~ 




RELATIVEIFRIEND'S INFORMATION SHEET 
PEOPLES' VIEWS ON CANCER CLINICAL TRIALS 
You are being invited to take part in a research study. The following information tells you why the 
research is being done and what it will involve. Please take time to decide whether or not you wish to 
take part. 
What is the purpose of this study? 
We are interested in what people think about clinical trials. We would like to work out what makes some 
people want to enter a trial and what makes others not want to. 
This study is NOT asking your relative to enter a clinical trial, we are just interested in your 
opinions. 
What is a Clinical Trial? 
A clinical trial is a study that tries to test whether a new treatment is better than an existing treatment. 
Although treatments for cancer have improved; we still do not know all the answers. Clinical trials are 
the means by which we find those answers. Involvement by patients in clinical trials is purely voluntary. 
In a trial a patient is randomised (selected by chance) to have either the standard treatment (which may 
be nothing) or the new treatment. 
Why have I been chosen? 
Your relative has been chosen because their cancer is newly diagnosed. Up to 200 other patients will also 
be studied over the next year. We are also asking a relative or friend who is close to the patient to help us 
with the study. 
Do I have to take part ? 
It is up to you whether or not you take part. If you do take part you will be asked to sign a consent form. 
You can withdraw from the study at any point. 
Your decision will not effect the standard of care your relative} friend receives. 
The study is separate from their medical care. The consultant will not be contacted about your or your 
relative's individual results. 
What will happen to me if I will take part? 
I Your questioonaires are on blue paper. 
2 After reading this information sheet please sign the consent form 
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APPENDIX XI (CONTINUED) 
3 Then complete the questionnaires. There are 3 in total This will take about 15 minutes in total, 
but you don't have to do them all at once. It is important that you fill them in before your 
relative's first clinic appointment. 
Only put your name on the questionnaire entitled "personal information". DO NOT put your 
name on the others. 
Please read the instructions on the questionnaires carefully and answer all questions. 
Please do not confer with your relative while filling them in. You are welcome to share answers 
afterwards! 
3. You should put the completed questionnaires in the envelope and give it to your relative for 
them to take to the clinic where they will be collected by a clinical trials nurse. Otherwise, they 
may post them back to us in the pre-paid envelope. 
Will my taking part be kept confidential? 
All information collected about you will be kept strictly confidential. All information that leaves the 
hospital will have your name removed from it. 
You will be given a participant number. 
What will happen to the results of the research study? 
The results of this study are likely to be published after the summer of2001. You will not be identified in 
any report or publication. We will send you a copy of the results if you wish. 
Who has reviewed this study? 
This study has been reviewed and passed by the Hull and East Riding Local Research Ethics Committee. 
Who should I contact for further information? 
Professor M. Lind. 
Department of Academic Oncology 
Princess Royal Hospital 
Salthouse Road 
Hull 
THANKYOU FOR TAKING PART IN TIlE STUDY 
You will be given a copy of this information sheet and a signed consent form to keep. 
29.08.00, version 2 
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APPENDIX XII 
RELATIVE/FRIEND'S CONSENT FORM 
Relative/friend identification number for the study D 
Title of Project: Psychological Factors that Influence Patient Participation in Cancer 
Clinical Trials. 
Name of researcher: Cheryl Jane Davis, Trainee Clinical Psychologist 
1. I confirm that I have read and understood the information sheet dated 29.08.00 (version 2) for the 
above study. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without legal rights being affected. CJ 
3. I agree to take part in the above named study. 
Name of relative/friend 
Name of person taking consent 










RELATIVEIFRIEND'S DEMOGRAPHIC INFORMATION 
Participant nwnber D 
PERSONAL INFORMATION 
Name 
Date of birth I I 
Occupation 
(ifhousewife. what is the occupation of your husband?) 
(if retired, what was your job previously?) 
Marital status: 




















HYPOTHETICAL TRIALS - RELATIVE/FRIEND'S VERSION 
This booklet contains descriptions of 4 situations sometimes faced by patients. 
These situations have been made up by us, but are based on previous real-life cases. 
Please read each one carefully and imagine that the situation is real. 
Circle the answer which best describes what you think your relative should do if faced with the 
decision. 
173 
APPENDIX XIV (CONTINUED) 
1 
Relative/friend 
Your consultant tells you that the standard treatment for your relative's Ifriend's disease will not 
help. 
However, there is a new (experimental) drug which may help. 
The consultant tells you about a clinical trial in which your relative/friend would either receive: 
no treatment 
or 
the new drug 
It would be decided by chance which of these they would receive. They would have an equal 
chance of receiving either one. 

















APPENDIX XIV (CONTINUED) 
2 
Relative/friend 
Your consultant explains to you that the standard treatment for your relative'slfriend's disease is 
drug A. There is also a new (experimental) treatment which may be helpful, drug B. 
Drug A has very few side effects. 
Drug B has a lot of side effects. 
There is a clinical trial where it will be decided by chance whether your relative/friend receives 
drug A or drug B. 
















APPENDIX XIV (CONTINUED) 
3 
Relative/friend 
Your consultant explains to you that the standard treatment for your relative's/friend's disease is 
drug A. There is also a new (experimental) treatment which may be helpful, drug B. 
Drug A has a lot of side effects. 
Drug B has very few side effects. 
There is a clinical trial where it will be decided by chance whether your relative/friend receives 
drug A or drug B. 

















APPENDIX XIV (CONTINUED) 
4 
Relative/friend 
Your consultant explains to you that there is no right or wrong treatment for your relative's/friend's 
disease. 
There are 2 treatments that are thought to be similarly helpful. 
They have similar side effects. 
There is a clinical trial where your relative/friend will receive one of these treatments. Which one 
they receive will be decided by chance. 


















ATTITUDES TO TRIALS AND RESEARCH QUESTIONNAIRE-
RELATIVE/FRIEND'S VERSION 
Please read each ofthe following questions and put a circle around your answer. If none of the 
options describes how you feel, just choose the closest one. Please answer all questions. 
We are interested in your opinions. There are no right or wrong answers. 









2) To develop new treatments for cancer, I think clinical trials are: 
1 2 3 4 
very somewhat neither somewhat 
necessary necessary needed unnecessary 
or 
not needed 























APPENDIX XV (CONTINUED) 
4) How much do you agree with this statement? 










5) How much do you agree with this statement? 
4 
disagree 


















6) How would participating in a trial, rather than receiving the standard treatment effect your hope 





















7) How do you think participating in a clinical trial would effect a patients' chance of survival 


















APPENDIX XV (CONTINUED) 
8) How much do you agree with this statement? 
















This means the patients who volunteer could receive anyone of the treatments in the trial. They 
cannot choose which one. 



















This means that neither the doctors or the patient would know which treatment the patient was 
receiving. 


















un com fortable 
APPENDIX XV (CONTINUED) 
11) How much do you agree with this statement? 
"If my doctor asked my relative/friend to participate in a clinical trial. I would feel that 















12) Iryour relative/friend were asked to participate in a clinical trial how much would you like them 







13) How much do you agree with this statement? 
4 
not at all 



















FOLLOW-UP INTERVIEW QUESTIONS 
1. 
Did you know anything about clinical trials before we approached you? 
What were your opinions? 
Did this study make you think abut trials? 
Did this study influence your decision? 
Did your opinions change when you were asked about the real trial? 
What are you opinions now? 
Looking back do you think you had any misconceptions about trials? 
Was there anything that went through your mind that you dismissed as being 'silly' or not important? 
2. 
Do you remember the hypothetical trials we gave you? 
How did you make your decision? 
Was it different when it came to the real trial? ..... How? 
3. 
How did you see your disease at that time? 
How did you feel about being faced with a decision like that? 
Should the patient have to decide? 
Did you feel the decision should be yours? 
Did it feel like a choice? 
4. 
What did the trial offer you? 
How much did you believe it would be a cure? 
What were your fears about the trial? 
Do you worry you've made the wrong decision? 
How do you predict feeling after the trial has ended what may you be thinking? 
5. 
Remembering yourself before the cancer, how are you different? 
How has your attitude towards life and illness changed? 
Would you volunteer for research again? 
6. 
Thinking about your family .... 
Did you discuss the trial with them, (prompt - what was their opinion) 
Was that helpful? 
How much did they influence your decision? 
Were your opinions alike at the start? 
Did they have any misconceptions about trials? 
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APPENDIX XVII 
HYPOTHETICAL TRIAL CORRELATIONS 
1 2 3 4 
Speannan's 1 Correlation 1.000 *.372 *.404 **.549 
rho Coefficient 
Sig.(2- .039 .024 .001 
tailed) 
N 31 31 31 31 
2 Correlation *.372 1.000 *·.717 *.393 
Coefficient 
Sig. (2- .039 .000 .029 
tailed) 
N 31 31 31 31 
3 Correlation *.404 **.717 1.000 *.448 
Coefficient 
Sig. (2- .024 .000 .011 
tailed) 
N 31 31 31 31 
4 Correlation **.549 *.393 *.448 1.000 
Coefficient 
Sig.(2- .001 .029 .011 
tailed) 
N 31 31 31 31 
• Correlation is significant at the .05 level (2-tailed) . 
•• Correlation is significant at the .01 level (2-tailed). 
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